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Abstract 
HIV-1 the Reverse Transcriptase (RT), the most renowned retroviral specific enzyme,  was the first 
anti-HIV target to be exploited, as. HIV-1 RT combines two functionsessential for viral replication: 
DNA polymerase, synthesis DNA either in a RNA dependent (RDDP) or DNA dependent (DDDP) 
manner, and Ribonuclease H (RNase H) . The RNase H activity catalyzes highly specific hydrolytic 
events on the RNA strand of the RNA/DNA replication intermediate, critical to the synthesis of 
integration-competent double-stranded proviral DNA. Because of its essential role, RNase H is a 
promising target for drug development. However, despite years of efforts,  no RNase H inhibitor 
(RHI) has yet reached  clinical approval.  
In this work we pursued the identification and characterization of new promising RHIs targeting 
either the RNase H active site itself (RNase H active site chelating agents) or both RNase H and 
RDDP activities (allosteric dual inhibitors). 
The first approach faced the challenging nature of the RNase H active site region, the morphology 
of wich is, more open than that of the relatively similar,HIV-1 integrase (IN). This  hampers the 
identification of a druggable pocket. We initially used Foamy Virus RT as a tool, to perform NMR 
and docking analyses on the interaction between  FV RT RNase H domain and a previously 
identified diketo acid (DKA) derivative, inhibitor RDS1643. The amino acid residues of  the FV 
RNase H active site region (T641, I647, Y672 and W703) were established to be important for the 
interaction with the inhibitor and analogous residues were successfully identified in the HIV-1 
RNase H domain using structural overlays. Further docking and site directed mutagenesis studies 
were performed using six couples of ester/acid DKA, derived from RDS1643, showing for the first 
time, a broad interaction between RHIs and conserved residues in the HIV-1 RNase H active site 
region (R448, N474, Q475, Y501 and R557). Moreover, ester and acid derivatives exhibited a 
different binding orientation, that reflected a different specificity for RNase H versus IN. Among 
the synthesised derivatives one, RDS1759, showed to be an RNase H selective active site inhibitor 
characterized also, for the first time,in cell-based assays. 
The second approach focused on the determination of the mechanism of action of a new isatine-
derived RNase H/RDDP dual inhibitor, RMNC6. Docking analysis and site directed mutagenesis 
7 
 
 
 
results suported the hypothesis of a two-sites mode of action, with an independent role for two 
pockets,to be further characterized for a rational optimization of the scaffold. 
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Chapter 1.  
Introduction  
 
Acquired immunodeficiency syndrome (AIDS) has been the object of intensive research since mid-
1981 when it was first described by the Center for Disease Control (CDC) (Anon 1981) and the 
scientific community deployed all  resources to halt the lethal progression of the disease. A new 
retrovirus, first categorized as a T-lymphotropic virus, HTLV-III, was reported to have been found 
in tissues from AIDS patients in 1983 (Barré-Sinoussi et al. 1983). The causative relationship 
between AIDS and this virus, later named Human Immunodeficiency Virus (HIV) (Coffin et al. 
1986), was established in 1984 (Broder & Gallo 1984). HIV-1 causes slow unremitting disease, 
targeting various lineages of CD4+ hematopoietic cells, particularly T-helper lymphocytes, 
differentiated macrophages, and some populations of dendritic cells. In particular, three different 
phases of infection have been characterized. The first, an “Acute retroviral syndrome” (ARS),  
occurs within 2-4 weeks after HIV infection in which the virus uses CD4+ cells to replicate 
massively, seeding and integrating its genome in various organs, particularly lymphoid organs such 
as the thymus, spleen, and lymph nodes. Plasma level of CD4+ cells drops down dramatically and a 
high number of HIV copies spread throughout the body. The immune system fights back with killer 
T cells (CD8+ T cells) and B-cell-produced antibodies. At this point, HIV levels in the blood are 
dramatically reduced. At the same time, CD4+ T cell counts rebound, and for some people the cell 
number rises to its original level. Shielded from the immune system, the virus lies dormant for an 
extended period of time, staying at a constant level called viral set point. During this second 
phase, called “Clinical latency stage”, the HIV virus continues to reproduce at very low plasma 
levels. For untreated people the clinical latency stage lasts an average of 10 years. During this time 
viral load will slowly begin to rise and CD4+ count to decline. The third phase, named as “full-
blown AIDS”, starts when the number of CD4 cells falls below 200 cells/mm3,: the human organism 
becomes vulnerable to opportunistic infections. Without treatment, people who progress to AIDS 
typically survive about 3 years, but the occurrence of dangerous opportunistic illnesses decreases 
the life-expectancy without treatment to about 1 year. The Joint United Nations Programme on 
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HIV/AIDS (UNAIDS) and World Health Organization (WHO)now estimates that the mean time from 
infection with HIV to AIDS and death, without treatment, is approximately 11 years. In 1986 a 
related, but immunologically distinct human retrovirus, now called HIV-2, was identified in Africa 
(Clavel et al. 1986). Compared to HIV-1, HIV-2 causes a slower decline in CD4+ levels, a longer 
clinical latency and a lower mortality rate (Gottlieb et al. 2002).  
Nowadays, over 30 years of intensive research on HIV-1 have transformed this highly lethal 
infection into a chronic disease (Tsibris & Hirsch 2010) that can currently be treated with 25 drugs 
in different therapeutic combination regimens. However, despite these efforts,  AIDS is still the 
first health emergency in the world. The last UNAIDS global report estimated 35.3 (32.2–38.8) 
million HIV-1 infected people and  2.3 (1.9–2.7) millions global new HIV infections in 2012. It has 
been estimated that more than 25 million people worldwide have already died of AIDS- related 
diseases and opportunistic infections, with an estimated 1.6 (1.4–1.9) million AIDS-related deaths 
in 2012 (Feinstein & Dimomfu 2013). Therefore the scientific community is still focusing on finding 
new targets and drugs to combat this threat.  
 
1.1 The Human Immunodeficiency Virus 1 
1.1.1 Genome Organization  
HIV-1 belongs to the family of Retroviridae, lentivirus genus. Like all prototypic lentiviruses, HIV-1 
has a (+) strand RNA genome that contains three major genes, gag, pol, env, encoding the major 
structural proteins as well as essential enzymes (Freed 2001). The HIV genome has several 
overlapping open reading frames and employs a sophisticated system of differential RNA splicing 
to obtain nine different gene products encoding 15 different proteins from its 9.2 kb genome. The 
three primary HIV-1 translation products are initially synthesized as polyprotein precursors, which 
are subsequently processed by viral or cellular proteases into mature proteins (Fig. 1). The gag 
gene encodes the proteins for the infrastructure of the internal part of the virus: the gag encoded 
p55gag protein is cutted during the virion maturation to obtain the structural proteins MA, CA, NC 
and p6 (Briggs et al. 2004). The pol reading frame codes for the  polyportein Pr160, subsequently 
cutted to originate the enzymes that are essential for viral replication: the integrase (IN), protease, 
and reverse transcriptase (RT). The env gene codes for the two subunits of the surface 
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glycoprotein complex gp120 and gp41. In addition, like most complex retroviruses, HIV-1 has 
multiple regulatory elements. The two main regulatory proteins are Tat and Rev, others important 
accessory proteins are  Nef, Vpr, Vif and Vpu, which are not essential for replication in certain 
tissues. Moreover, several conserved secondary structure elements, also called cis-acting RNA, 
have been identified within the HIV-1 RNA genome, as series of stem-loop structures connected by 
small linkers. These  include the trans-activation region (TAR) element, the  5'-polyadenylation 
signal [poly(A)], the Primer bindig site (PBS), the dimeriziation intiation sequence(DIS), the major 
splice donor(MSD) and the ψ hairpin structure located within the 5' end of the genome and the HIV 
Rev response element(RRE) within the env gene (Damgaard et al. 2004). These elements are 
reported to mediate elongation of viral RNA transcripts, genomic RNA dimerization, splicing and  
packaging of full length viral RNA (Freed & Martin 2007). 
 
 
 
 Figure 1. Human Immunodeficiency virus encoded proteins. The location of HIV genes, the sizes 
of primary translation products and the processed mature viral proteins are indicated. Modified 
from (Freed & Martin 2007). 
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1.1.2 Structure  
The virion of HIV-1 is a roughly spherical particle with a diameter between 100 and 180 nm 
(Ganser-Pornillos et al. 2012). The virion is surrounded by a cell-derived lipid membrane 
containing surface proteins. Some of these membrane proteins are products of the viral genome 
(surface glycoprotein gp120/gp41), while others are captured from the host cell during viral 
budding and can perform supporting functions. Directly below the viral lipid membrane is a matrix 
layer composed of trimers of matrix protein (p17). Inside the HIV particle is a cone-shaped 
structure, named capsid, composed of approximately 250 hexamers and 12 pentamers of capsid 
protein (p24). The capsid contains two copies of positive single-stranded viral RNA bound by the 
NC (p7) protein and the enzymes (RT and IN) necessary for replication of the virus (Fig. 2). 
 
Figure 2. Schematic representation of the mature HIV-1 virion structure.  
 
1.1.3 Viral replication cycle  
Once in the host organism, HIV-1 uses the gp120/gp41 glycoprotein to target the CD4 receptor 
located on the surface of susceptible cells. A subsequent conformational switch allows the 
interaction with chemokine co-receptors CXCR4 and CCR5 on the cell surface, promoting the 
fusion of viral and cell membranes (Doms 2000). During entry, the disaggregation of the matrix 
shell permits the release of the core in the host cytoplasm. Here subviral particles are partially 
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uncoated maintaining protection of the viral RNA genome while permitting access to the 
deoxyribonucleoside triphosphates (dNTPs) necessary for proviral DNA synthesis. The genomic 
RNA is reverse transcribed into a linear integration competent double-stranded DNA molecule, 
which, associated with IN and viral cofactors in the “preintegration complex”, is imported into the                                                                                                                                                      
 
Figure 3.  HIV-1 replication cycle. 1. Fusion of the HIV cell to the host cell surface. 2. HIV RNA, 
reverse transcriptase, integrase, and other viral proteins enter the host cell.3 Viral DNA is formed 
by reverse transcription. 4.Viral DNA is transported across the nucleus and integrates into the host 
DNA. 5.New viral RNA is used as genomic RNA and to make viral proteins. 6.New viral RNA and 
proteins move to cell surface and a new, immature, HIV virus forms. 7.The virus matures by 
protease releasing individual HIV proteins. Source modified from : National Institute of Allergies 
and Infectious Diseases, Biology of HIV. 
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nucleus and integrated into the host genome (Fig.3). The integration of viral DNA is catalyzed by 
the viral coded enzyme IN and enhanced by the viral nucleic acid chaperone protein NC, which 
also protects viral DNA from degradation. HIV-1 preferentially integrates in active transcriptional 
units in human cells. The stably integrated HIV-1 provirus serves as a template for the 
transcription of viral messengers and genomic RNA by the cellular RNA polymerase II. The viral 
promoter, situated in the U3 part of the 5’-LTR (Fig.5), requires activation by cellular transcription  
factors, together with the binding of the viral transactivator protein Tat to the stem-loop trans-
acting response element (TAR) present in 5’-LTR region. The synthesized full length HIV-1 
transcripts are transported to the cytoplasm either unspliced (genomic RNA, which also serves as 
the Gag and Gag-Pol mRNA), partially spliced (encoding Vif, Vpr, Vpu and Env) or fully spliced   
(encoding Tat, Rev and Nef). The viral Rev protein links the incompletely spliced and unspliced viral 
RNAs to the export machinery, allowing unspliced RNA to exit from the nucleus. In the cytoplasm, 
mRNAs are translated into viral proteins and the enzymatic polyproteins precursors Gag and Gag-
Pol. These are transported via different pathways to the plasma membrane, where they 
concentrate in lipid rafts that putatively serve as assembly platforms, while other components 
accumulate close by. When the number of densely packed viral polyproteins beneath the plasma 
membrane reach  1500 to 2000 units, it induces membrane curvature and then the subsequent 
formation of a membrane-coated spherical particle. The HIV-1 p6 part of Gag mediates the final 
viral release. The newly released particles have an immature morphology, whitout a condensed 
core. Shortly after the budding is finished, the viral protease is auto-activated and cleaves both 
Gag and Gag-Pol precursors into their sub-components wich then reorganize into the 
characteristic conical inner core. 
 
1.2 Approved HIV-1 inhibitors 
The HIV-1 life cycle, with its many steps and virus-regulated or catalyzed events, presents many 
potential opportunities for therapeutic intervention (Fig. 4). During the entry, Gp41 and the 
coreceptor CCR5 are the targets for two approved entry agents: the peptide-based fusion 
inhibitor, enfuvirtide, and the small-molecule CCR5 chemokine receptor antagonist, maraviroc. 
The second critical step of  the replication cycle is the reverse transcription of (+) ssRNA genome, 
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wich lasts the first 10 hours of infection and is the target for two distinct classes of RT inhibitors 
(RTI): the nucleoside RTIs (NRTIs) zidovudine, didanosine, zalcitabine, stavudine, lamivudine, 
abacavir, emtricitabine and tenofovir, all of which are analogs of native nucleoside substrates, and 
the non-nucleoside RTIa (NNRTIs) delavirdine, efavirenz, etravirine, nevirapine and rilpivirine, all of  
which bind to a non-catalytic RT allosteric pocket. Both RTI classes affect the RT DNA 
polymerization activity and block the generation of full-length viral DNA. A third step targeted by 
approved drugs is the proviral DNA integration. Two IN inhibitors (INIs) are currently available: 
Raltegravir and the recently licensed Dolutegravir. Both of them specifically inhibit IN strand-
transfer activity and block the integration of the HIV-1 DNA into the cellular DNA. A fourth  process 
blocked by HIV-1 approved inhibitors is the processing of viral polyproteins by the viral encoded 
Protease that is the target of eight approved drugs: atazanavir, fosamprenavir, daruavir, ritonavir, 
nelfinavir, squinavir, tipranavir, indinavir. 
 Figure 4.  Schematic of the HIV-1 life cycle in a susceptible CD4+ cell. Potential or current 
antiretroviral drug target are higlighted .  FDA-approved inhibitors are listed in relation to 
specificity of action and drug target (Modified from Arts et al. 2012).  
 
1.3 Retrotranscription process 
Among the 25 HIV-1 inhibitors, the 12 drugs that target the reverse transcription account for 
nearly half of all approved antiretroviral drugs. The retrotranscription process (Fig. 5) is 
characteristic of all retroviruses and requires viral as well as cellular elements among which the 
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most important is the virus-encoded RT protein, a multifunctional enzyme that performs the viral 
genome replication using two associated enzyme functions: DNA polymerase and ribonuclease H 
(RNase H). 
As briefly introduced before, each HIV particle contains two copies of (+) ssRNA genome sequence 
9,2 kb long (Ratner et al. 1985), which codes for structural and non-structural proteins and has 
two identical sequences at its the 5’- and 3’-ends,. Near the 5’-end of the viral genome there is a 
18 nucleotides long segment, termed primer binding site (PBS), that is complementary to the 3’ 18 
nucleotides of the human tRNALys3. When the cellular tRNA is hybridized to the PBS, it serves as a 
DNA primer and the RT-associated DNA polymerase function can initiate the first (-) strand ssDNA 
synthesis using the viral RNA genome as a template. The (-) strand ssDNA synthesis generates an 
RNA:DNA hybrid that is a substrate for the RT-associated RNase H function which selectively 
degrades the RNA strand of the RNA:DNA hybrid. During (-) ssDNA synthesis, RT pauses at the TAR 
hairpin, realizing the first (-) strand strong-stop DNA and promoting RNA cleavage approximately 
14-20 nucleotides downstream from the pause site within the polyA hairpin in the copied 
template. This cleavage exposes the (-) ssDNA to an interaction with the polyA hairpin present in 
the R sequence of the 3’ end genome. Therefore, a (-) strand-transfer occurs from the R region at 
the 5’-end of the genome to the equivalent R region at the 3’-end. The presence of two RNA 
genome molecules in a single virion particle allows (-) strand strand-transfer to occur either intra- 
or inter-molecularly (Chen et al. 2003). After this step, (-) strand synthesis can continue along the 
viral RNA starting from its 3’-end. Whilst DNA synthesis proceeds, the RNase H function cleaves 
the RNA strand of the RNA:DNA at numerous points. Although most of the RNase H cleavages do 
not appear to be sequence specific, there are two conserved purine-rich sequences, known as the 
polypurine tracts (PPTs), that are resistant to RNase H cleavage and remain annealed to the 
nascent (-) strand DNA. These two well-defined sites are located in the central part of the HIV-1 
genome. In particular, the 3’-end PPT defines the 5’-end of the viral coding (+) strand DNA 
synthesis since this PPT serves as DNA primer (Huber & Richardson 1990; Rausch & Le Grice 2004). 
The (+) strand DNA synthesis continues until the 5’-end of the (-) strand DNA and also uses the 18 
nucleotide PBS sequence of the tRNA as a template. Importantly, the 19th base from the 3’-end of 
tRNALys3 is a methylated Alanine, and the presence of this modified base blocks the RT,  
16 
 
 
 
 
Figure 5. HIV-1 reverse transcription process. Step 1: host cell tRNALys3 hybridizes to the PBS 
near the 5’-end of the (+) strand RNA genome (orange). (-) strand DNA (blue) synthesis starts using 
host tRNALys3 as a primer. DNA synthesis proceeds up to the 5’-end of the RNA genome. Step 2: 
RNase H hydrolysis of the RNA portion of the RNA:DNA hybrid product exposes the ssDNA product 
determining the (-) strand strong stop DNA. Step 3: strand transfer of the (-) strand DNA through 
its hybridization with the R region at the 3’-end of the ssRNA genome and further elongation of 
the (-) strand DNA. Step 4: DNA synthesis proceeds and the RNase H function cleaves the RNA 
strand of the RNA:DNA at numerous points leaving intact two specific sequences (cPPT, 3’PPT) 
resistant to the RNase H cleavage. Step 5: (-) strand DNA synthesis (green) initiation using PPTs as 
primers. Step 6: RNase H hydrolysis of the PPT segments and the junction of the tRNA:DNA hybrid, 
freeing the PBS sequence of the (+) strand DNA. Step 7: strand transfer of the PBS sequence of the 
(+) strand DNA that anneals to the PBS on the (-) strand DNA. DNA synthesis then continues with 
strand displacement synthesis. Step 8: the product is a linear dsDNA with long terminal repeats 
(LTRs) at both ends. From (Esposito et al. 2012). 
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generating a (+) strand strong-stop DNA. Subsequently, the RNase H function precisely cleaves the 
RNA segment of the tRNA:DNA hybrid, freeing the PBS sequence of the (+) strand DNA 
andallowing it to anneal to the complementary site near the 3’-end of the extended  (-) strand 
DNA (Basu et al. 2008). Then, a bidirectional synthesis occurs to complete a viral dsDNA that has a 
90 nucleotides single-stranded flap at the center. This unusual situation is thought to be solved by 
host mechanisms and one candidate for flap removal is the flap endonuclease-1 (FEN-1) (Rausch & 
Le Grice 2004). Finally, a specific RNase H cut removes the PPT primers and exposes the 
integration sequence to facilitate the insertion of the viral dsDNA into the host chromosome.  
 
1.4. RT structure and functions 
As a major target for anti-HIV therapy, RT has been the subject of extensive research through 
crystal structure determinations, biochemical assays and single-molecule analyses. RT derives 
from a Gag-Pol polyprotein that is processed by the viral-encoded protease to give rise to two 
related subunits of different length, p66 and p51, that share a common amino terminus and 
combine in a stable asymmetric heterodimer (Divita et al. 1995). Analysis of the crystal structure 
of RT (Fig. 6) reveals that p66 is composed of two spatially distinct domains: the polymerase 
domain and the RNase H domain. The polymerase domain shows a characteristic highly conserved 
right hand-like structure, consisting of the fingers domain (residues 1-85 and 118-155), the palm 
domain (residues 86-117 and 156-237) and the thumb domain (residues 238-318). The p66 subunit 
also comprise the connection domain (residues 319-426) and RNase H domain (residues 427-560) 
(Kohlstaedt et al. 1992; Jacobo-Molina et al. 1993). The p51 subunit lacks the RNase H domain and 
has the same four subdomains of the p66 polymerase domain. The relative subdomain positions, 
however, are different from p66. Because of its different folding, p51 does not have enzymatic 
activities but serves to stabilize the proper folding of the p66 subunit which performs all the 
catalytic functions (Esposito et al. 2012).  
RT is primarily responsible for several distinct activities that are all indispensable for the 
retrotranscription process: RNA- and DNA-dependent DNA synthesis, RNase H activity, strand-
transfer, and strand displacement synthesis (Liu et al. 2008). The presence of all these functions in 
a single protein together with  its highly dynamic RT nature which allows it to spontaneously slide 
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over long distances of RNA:DNA and DNA:DNA duplexes, to  target the primer terminus for DNA 
polymerization, to rapidly access multiple sites and, hence, to make up for its low processivity. RT 
sliding does not require energy from nucleotide hydrolysis, and it is thought to be a thermally 
driven diffusion process (Liu et al. 2008). 
It has recently been shown that RT can bind to the nucleic acid substrates in two different 
orientations, termed “RNase H cleavage competent orientation” and “polymerase competent 
orientation”, each of which allows  one of the two enzymatic activities (Abbondanzieri et al. 2008). 
These two binding modes are in a dynamic equilibrium and it has been demonstrated that RT can  
 
  
Figure 6. Structure of HIV-1 RT. The enzyme has two domains: the p66 (colored) and the p51 
(gray). The polymerase domain shows a characteristic highly conserved structure that resembles a 
right hand, consisting of the fingers domain (magenta),the palm domain (cyan), and the thumb 
domain (blue). The p66 subunit also comprises the connection domain (orange) and RNase H 
domain (yellow). The polymerase active site is located in the middle of the palm, fingers and 
thumb subdomains. The three catalytic aspartic acid residues (D110, D185 and D186) located in 
the palm subdomain of p66 that bind the cofactor divalent ions (Mg2+) are shown (red). The RNase 
H domain is located at C-terminus of the p66 subunit, 60 Å  from the polymerase active site. The 
RNase H active site contains a DDE motif comprising the carboxylates residues D443, E478, D498 
and D549 (shown in red) that can coordinate two divalent Mg2+(shown as a cream spheres). 
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spontaneously and rapidly switch between these orientations without dissociating from the 
substrate. This flipping can be influenced by the presence of small molecules such as nucleotides, 
that stabilize the polymerase competent orientation, or NNRTI inhibitors that, conversely, 
destabilize it (Abbondanzieri et al. 2008). Together, shuttling and switching, give rise to a very 
complex series of conformational changes that increase the replication efficiency. 
 
1.4.1 RNA- and DNA-dependent DNA synthesis 
The DNA synthesis, catalyzed by both RT-associated RNA- and DNA-dependent DNA polymerase 
activities (RDDP and DDDP, respectively), occurs with a mechanism that is similar to the one of all 
others DNA polymerases (Steitz 1999) The polymerase active site is located in the middle of the 
palm, fingers and thumb subdomains. In particular, the thumb subdomain is very important for a 
correct substrate binding since its β12– β13 sheets,termed the “primer grip”,  extensively interact 
with the phosphate backbone (Dash et al. 2008). Three aspartic acid residues (D110, D185 and 
D186) located in the palm subdomain of p66 bind the divalent ion cofactor (Mg2+) through their 
catalytic carboxylate groups and are essential for catalysis (Fig. 6) (Sarafianos et al. 2009). The DNA 
synthesis requires that RT binds to the template primer on the priming binding site, and this 
interaction is stabilized by a change of the conformation of the thumb (from close to open). Then, 
an incoming dNTP is admitted on the nucleotide binding site to form a ternary complex. Then, a 
conformational change of the fingers traps the dNTP, precisely aligning the α-phosphate of the 
dNTP and  the 3’-OH of the primer inside the polymerase active site (this is the rate limiting step). 
Now, the enzyme catalyzes the formation of a phosphodiester bond between the primer 3’-OH 
and the dNMP, while releasing  a pyrophosphate. The fingers weaken the grip around the 
substrate and allow the pyrophosphate free to leave the catalytic site. Finally, a translocation of 
the elongated DNA primer frees the nucleotide-binding site for the next incoming dNTP. 
Alternatively RT can dissociate from the complex. Compared to cellular DNA polymerases, RT 
exhibits a very low processivity, typically dissociating from the substrate after synthesizing only a 
few hundred nucleotides. This fact decreases the RT fidelity and results in the accumulation of 
mutations during reverse transcription. Error rates have been reported to fluctuate between 5.8 x 
10-5 and 1.2 x 10-5  per nucleotide per replication cycle. Precise rate differ between different HIV-1 
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genetic subtypes and significantly increase at temperatures above 37°C (Menéndez-Arias 2008; 
Álvarez & Menéndez-Arias 2014).  
Importantly, during its DNA polymerase activity RT can run up against several template secondary 
structures, particularly in case of the RNA template that can form stable RNA:RNA interactions, 
which can occlude the polymerization site and/or displace the primer terminus. In this case, RT has 
been shown to realize a strand displacement synthesis, in which the sliding movement can 
contribute to the re-annealing of the primer, displacing the RNA (Sarafianos et al. 2009). 
 
1.4.2 RNase H: DNA-directed RNA cleavage 
RT is able to nonspecifically hydrolyze the RNA strand of the RNA:DNA replication intermediate, as 
well as to catalyze highly specific hydrolytic events. Prominent among these is precise removal of 
the RNA primers that initiate (-) and (+) strand DNA synthesis (a host-coded tRNA and the poly- 
purine tract, respectively).These events ultimately define 5´- and 3´-LTRs, sequences that are 
essential for efficient integration of viral DNA. This RNase H function is essential for virus 
replication as RNase H-deficient viruses are non-infectious (Schatz et al. 1990). 
The RNase H domain is located at the C-terminal end of the p66 subunit, 60 Å far from the 
polymerase active site (Fig. 6). This distance is equivalent to the length of 17 nucleotides of a 
DNA:DNA duplex or 18 nucleotides of a RNA:DNA hybrid (Nowotny et al. 2005). The RNase H 
active site contains a highly conserved, essential DDE motif, which includes the carboxylate 
residues  D443, E478, D498 and D549. These coordinate two divalent Mg2+ cations, consistent with 
the proposed phosphoryl transfer geometry (Rosta et al. 2011). Mutations in any of the D443, 
D498 and E478 residues abolish enzyme activity (Schatz et al. 1989; Mizrahi et al. 1990; Mizrahi et 
al. 1994). The RNase H domain can catalyze a phosphoryl transfer through nucleophilic 
substitution reactions on phosphodiester bonds. This action occurs through the deprotonation of a 
water molecule, producing a nucleophilic hydroxide group that attacks the scissile phosphate 
group of RNA previously activated by coordination with the Mg2+ cofactor (Beilhartz & Götte 
2010). RNase H cleavage specificity for the RNA portion of RNA:DNA hybrid mainly relies on the 
particular minor groove width of such hybrids and its interaction with the “primer grip” . The latter 
refers to an extensive network of contacts between the hybrid phosphate backbone and several 
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residues ∼ 4-9 bp far from the RNase H active site (Dash et al. 2008). The RNA:DNA helical 
structure has a minor groove width of ∼ 9-10 Å, which is intermediate between the A- and B-form 
of the others double-stranded nucleic acids (dsNA). The HIV-1 RNase H hydrolyzes hybrids with 
lower monor grove widths much less efficiently, such as the PPT containing hybrids which  show a 
widths of only 7 Å probably due to the presence of polyA-tracts.(Sarafianos et al. 2001; Sarafianos 
et al. 2009) This fact allows recognition of PPT sequences as RNA primers for DNA synthesis by RT, 
and may also represent a further specific target for development of antiviral drugs.  
The RNase H catalysis can occur “polymerase-dependently” or “polymerase independently”, and it 
is possible to distinguish three different cleavage types “(Menéndez-Arias et al. 2008; Champoux & 
Schultz 2009). “DNA 3’-end-directed cleavage” acts during (-) strand DNA synthesis, when the 
RNase H active site cleaves the RNA in a position based on the binding of the polymerase active 
site to the 3’-end of the new (-) DNA (Furfine & Reardon 1991). “RNA 5’-end-directed cleavage” 
acts when RT binds to a recessed RNA 5’-end annealed to a longer DNA strand, and  RNase H 
function cleaves the RNA strand 13-19 nucleotides away from its 5’-end. The “internal cleavage” 
cleavage occurs because the RNA cleavage is slower than DNA synthesis and, given that, a viral 
particle contains 50-100 RT molecules and only two copies of (+) RNA, all non-polymerizing RTs 
can bind to the hybrid and degrade the RNA segment by a polymerase-independent mode (Dash 
et al. 2008) 
 
1.4.3 Strand-transfer  
The strand-transfer is a critical step during the reverse transcription process in which two 
complementary ssNAs have to anneal to allow the completion of DNA synthesis. In both the (-) 
and (+) strand transfer the ssNA develops secondary structures: the 97 nt R element folds into two 
conserved stem loop structures: the trans activation response element (TAR) and a poly(A) hairpin 
(Goff 2007; Damgaard et al. 2004). The PBS sequence at the 3’-end of the (-) strand DNA can also 
form a stable hairpin structure. Strand transfer by RT is promoted by the presence of viral-
encoded nucleocapsid (NC) protein (Ji et al. 1996). The strand transfer process, together with the 
RT fidelity and the presence of other host factors such as APOBEC (Aguiar & Peterlin 2008) 
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underlie the high rates of mutagenesis and recombination, events that allow HIV to rapidly evolve 
and develop resistance against drugs. 
 
1.4.4 Pyrophosphorolysis 
Like most DNA polymerases, RT can catalyze the reversal of the dNTP incorporation, whichis 
termed pyrophosphorolysis. RT uses a pyrophosphate (ppi) molecule or an NTP, such as ATP, as 
acceptor substrate (Arion et al. 1998). The reaction produces a dinucleotide tetraphosphate 
(formed by the excised dNMP and the acceptor ATP substrate), leaving free the 3’-OH DNA end. 
This RT function is particularly important in some drug resistant mechanisms.This will be sicussed 
more in detail later on. 
 
1.5 RTIs: structure, mode of action and resistance 
The approved combination treatments used for HIV-1 include two classes of RTIs that target the 
viral enzyme with two different mechanism of action. The first class comprises compounds known 
as NRTIs while the second class comprises compounds known as NNRTIs. 
 
1.5.1 Nucleoside and Nucleotide RT inhibitors (NRTIs and NtRTIs) 
There are currently eight NRTIs clinically available, structurally resembling both pyrimidine and 
purine analogues (Mehellou & De Clercq 2010; Arts & Hazuda 2012; Esposito et al. 2012) (Fig. 7). 
Pyrimidine nucleoside analogues include thymidine analogues zidovudine (AZT), stavudine (d4T) 
and cytosine analogues such as lamivudine (3TC), zalcitabine, (ddC), emtricitabine (FTC) . Purine 
nucleoside analogues include abacavir (ABC) and didanosine (ddI), guanosine and adenine 
analogues, respectively. In order to inhibit reverse transcription, these agents have to be 
phosphorylated by cellular kinases to their triphosphate derivatives. All NRTIs follow the same 
mechanism of RT inhibition: once activated to their triphosphate form, they enter the DNA 
polymerase active site (Fig. 5) and are incorporated by RT into the growing DNA competing with 
the natural dNTPs and terminating the elongation of the growing dsDNA due to their lack of a 3’-
hydroxyl group (Fig. 7). Therefore, once incorporated into dsDNA they prevent the further 
incorporation of incoming nucleotides. Importantly, while the HIV-1 RT uses these NRTIs as 
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substrates, the cellular DNA polymerases do not recognize them with the same affinity. The 
“second-generation” nucleoside analogues (Mehellou & De Clercq 2010) are also equipped with a 
phosphonate group which cannot be cleaved by hydrolysis (by esterases), making them more 
resistant to cleavage once incorporated compared to their regular dNTP counterparts. The only 
approved member of this class is tenofovir (PMPA). 
Under selective drug pressure, viral mutants resist to NRTIs by two general mechanisms: NRTI 
discrimination , which reduces the NRTI incorporation rate usually by steric hindrance (Schinazi 
1993, Schuurman 1995), and NRTI excision, which eliminates NRTI after incorporation. The M41L, 
D67N, D70R, L210W, T215F/Y and K219Q mutations, located around the dNTP binding pocket and 
also termed thymidine analogs mutations (TAMs), increase NRTI excision (Fig. 8) (Arion et al. 1998; 
Dharmasena et al. 2007; Yahi et al. 2005; Meyer et al. 1999). Recently, mutations in the 
connection and RNase H domains have also been shown to confer NRTI resistance (Nikolenko et al. 
2007; Yap et al. 2007; Delviks-Frankenberry et al. 2008; Brehm et al. 2007; Hachiya et al. 2008) by 
reducing RNase H activity. This RNase H-dependent mechanism of NRTI resistance has been 
proposed to be due to an increase in NRTI excision determined by a reduction of RNase H activity, 
because the time available for nucleotide excision is limited by the degradation of the template by 
RNase H. Therefore, when mutations in the RNAse H domain decrease its activity and 
consequently the HIV-1 RT template-switching, the excision rate is augmented, but only during 
RNA-dependent DNA synthesis and not during DNA-dependent DNA synthesis(Roquebert & 
Marcelin 2008)  
 
1.5.2 Non-Nucleoside RT Inhibitors (NNRTIs) 
NNRTIs are a structurally and chemically diverse group of  compounds that inhibit RT by binding to 
the enzyme in a hydrophobic pocket (NNIBP) located in the palm domain of the p66 subunit of the 
heterodimeric RT, approximately 10 Å from the catalytic site of the enzyme. This class counts five 
approved drugs with remarkably heterogeneous scaffolds: nevirapine, efavirenz, delavirdine, 
etravirine and rilpivirine (Fig. 8). 
The NNRTI binding pocket contains the side chains of aromatic and hydrophobic amino acid 
residues Y181, Y188, F227, W229, Y318, P95, L100, V106, V108, V179, L234 and P236 from the p66 
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 Figure 7. Chemical structures of approved NRTIs and NNRTIs.  
 
Figure 8. Pockets involved in RDDP inhibitor binding to HIV-1 RT. The two HIV-1 RT subunits are 
in green (p66) and in gray (p51). The catalytic residues of the RDDP active site are shown in red. 
NRTIs interact with residues close to the polymerase active site, some of which are mutated in 
TAM resistant viruses (blue). NNRTis bind in a hydrophobic pocket next to the polymerase active 
site (dark pink).  
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subunit (Distinto et al. 2013) (Fig. 8). The NNIBP is flexible and its conformation depends on the 
size, shape, and binding mode of the different NNRTI. It can accommodate a space of about 620-
720 Å, which is approximately more than twice the volume occupied by most of the present 
NNRTIs. This explains the large variety of chemical scaffolds of this class of inhibitors (Mehellou & 
De Clercq 2010) whose shapes inspired authors to create imaginative names to describe them, e. 
g. “butter- fly” (Ding et al. 1995), “horseshoe” (Das et al. 2005) and “dragon” (Das et al. 2011). The 
binding of NNRTI causes the dislocation of the β12-β13- β14 sheets that results in a movement of 
the primer grip away from the polymerization site sheet (Das et al. 1996). Importantly, unlike 
NRTIs, NNRTIs do not require intracellular metabolic processing to exert their activity. The 
stabilization of the NNRTI binding in the allosteric site is accomplished through i) stacking 
interactions between the NNRTI aromatic rings and the side chains of Y181, Y188, W229 and Y318 
residues in the lipophilic pocket of the RT; ii) electrostatic forces (particularly significant for K101, 
K103 and E138 residues); iii) van der Waals interactions with L100, V106, V179, Y181, G190, W229, 
L234 and Y318 residues; iv) hydrogen bonds between NNRTI and the main chain (carbonyl/amino) 
peptide bonds of the RT (Mui et al. 1992; Schäfer et al. 1993; Balzarini 2004). First-generation 
NNRTIs, such as nevirapine and delavirdine, easily become ineffective through selection of  
resistant RTs that contain single aminoacid mutations. Such commonly observed resistance 
mutations in NNRTI-treated patients include L100I, K103N, V106A, Y181C, Y188L, and G190A (Ren 
& Stammers 2008). These mutations occur alone or in combination and cause clinically relevant 
drug resistance, directly, by altering the size, shape, and polarity of different parts of the NNIBP or, 
indirectly, by affecting access to the pocket.  
 
1.6. RNase H function as a drug target 
Because of its peculiar role,  RNase H function has been the object of intensive efforts to identify 
RNase H inhibitors (RHIs), and, throught the past decade, a number of classes of molecules able to 
inhibit RNase H function have been identified (Tramontano 2006; Tramontano & Di Santo 2010; 
Corona et al. 2013). RNase H inhibitors can be categorized in two classes based on their binding 
site and mode of action: metal-chelating active site inhibitors (Fig.9) and allosteric inhibitors 
(Fig.10).  
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Figure 9. Chemical structure of RNase H active site inhibitors.  
 
1.6.1 Metal chelating active site inhibitors.  
Metal chelating active site inhibitors binds into the RNase H active site coordinating the two Mg2+ 
ion cofactors. The first reports of a compound inhibiting RNase H function was a diketoacid (DKA) 
derivative ,BTBA, which was first developed against  HIV-1 IN (Shaw-Reid et al. 2003), and N-
Hydroxyimides (Klumpp 2003). The first proof of RHI DKA RDS1643  inhibits viral replication 
(Tramontano et al. 2005) encouraged the development of different classes of Mg2+ chelating 
agents: hydroxilated tropolones betathujaplicinol (BTP) and manicol, (Budihas et al. 2005; Chung 
et al. 2011), hydroxypyrimidines (Kirschberg et al. 2009) and hydroxyquinazolinediones (Lansdon 
et al. 2011), naphthyridinones (Su et al. 2010), Nitrofuran-2-carboxylic Acid Carbamoylmethyl 
Esters (NACME) (Fuji et al. 2009), thiocarbamates and triazoles (Di Grandi et al. 2010) (Fig. 9). 
Unfortunately, in all co-crystallized structures of RT/RNase H prototypes with RNase H inhibitors 
coordinating the cofactors into the active site (Chung et al. 2011; Su et al. 2010; Klumpp & 
Mirzadegan 2006; Lansdon et al. 2011)  the compounds exhibited an orientation of binding that 
did not allow extended secondary interactions between enzyme and inhibitor, with the exception 
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of residue H539 (Lansdon et al. 2011), not allowing further insights for improve  binding affinity 
and inhibitor specificity. 
 
1.7.2 Allosteric inhibitors.  
A number of structurally different compounds have been reported to inhibit HIV-1 RNase H 
activity without chelation (Corona et al. 2013). Among them are Vinylogous Ureas (Chung et al. 
2010) (Chung et al. 2012), Thienopyrimidinones (Masaoka et al. 2013), Anthraquinones (Esposito 
et al. 2011), Hydrazones (Himmel 2006), and isatine derivatives  (Distinto et al. 2013) (Fig. 10). 
These classes of compounds exhibited different binding in three different allosteric pockets. 
In particular, vinylogous urea and thienopyrimidinone derivatives have been proposed to occupy a 
site at the interface of the two RT subunits that comprises p51 subunit residues C280-T290 and 
p66 subunit P537-E546 (Chung et al. 2012) (Fig. 11). Since x-ray crystal data suggests that the 
RNA/DNA hybrid binding is accompanied by movement of the p51 thumb and p66 RNase H 
domain as a single unit, it has been proposed that these compounds inhibit the 
subdomain/subunit flexibility that is an integral component of catalysis. In perspective, given the 
requirement for RT flexibility in accommodating and processing the RNA/DNA replication 
intermediate, the subunit interface may indeed offer a druggable pocket for compounds that can 
alter the RT subdomain and subunit motion.  
Other compounds such as Hydrazones (Himmel et al. 2006), anthraquinones (Esposito et al. 2011) 
and isatine derivatives (Distinto et al. 2012) have been reported to have an interesting dual 
inhibition profile, since they inhibit both RT-associated RNase H and RDDP functions. They have 
been proposed to bind either to i) an allosteric site located between the polymerase catalytic 
region and the pocket where most of known polymerase inhibitors bind (50 Å from the catalytic 
site) including amino acid residues V108, D186, L187, Y188, L223, P227, L228 and W229 (Himmel 
et al. 2006); ii) a site located between the RNase H active site and the substrate-handle region 
including amino acid residues W401, T403, E404, K431, E430,Q507, and W535 on p66 and K331, 
L422 and L425 on p51. (Felts et al. 2011); iii) both sites at the same time (Distinto et al. 2013) (Fig. 
11). 
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Figure 10.  Chemical structure of allosteric RNase H inhibitors  
 
Figure 11. Pockets involved in RHI binding to HIV-1 RT. The two HIV-1 RT subunits are shown in 
green (p66) and in gray (p51). The catalytic residues of the RNase H active site are enlightened in 
red. The Hydrazone binding site, described by Himmel et al (Himmel et al. 2006), is located 
between the polymerase active site and the NNRTI binding pocket (sharing a few residues with it) 
(purple). A second Hydrazone binding site proposed by Felts et al (Felts et al. 2011),is located 
between the RNase H and the connection domain (yellow). The putative binding site for 
Vinylogous ureas is a hydrophobic pocket at the interface between the RNase H  domain and the 
p51 subunit (cyan). 
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The high RT plasticity, together with the notion that NNRTIs such as nevirapine and efavirenz show 
long-range effects ( increased RNase H catalytic activity) have led to the proposal of combinated of 
short-range and long-range effects for the inhibition of RDDP and RNase H functions (Distinto 
2013). However, the real mechanism of action is not determined yet and the role played by the 
two binding sites is controversial. 
 
1.7 Objectives 
The HIV-1 RT-associated RNase H function is essential for retroviral replication and is an attractive 
drug target given that no RNase H inhibitor has been approved yet. The purpose of this thesis 
work has been to identify and characterize new selective and potent RNase H inhibitors to be 
further developed into drug candidates.  
Given the available informations produced in the field of RNase H inhibition until 2011 by my 
research group at the University of Cagliari, I pursued this goal focusing both on characterization 
of RNase H active site chelating agents and on determination of the mechanism of action of RNase 
H and RDDP dual inhibitors, starting either from already identified RNase H inhibitors or new 
promising scaffolds, identified in our laboratory by virtual and in vitro screening.  
In both cases I carried out a combination of in vitro and in silico analysis to understand the 
chemical determinants involved in the binding of the inhibitor to the targeted protein. I explored 
the putative binding sites, dissecting the pocket/s by site-directed mutagenesis of residues 
hypothesized to be critical for binding. Finally, when possible, I validated the target in cell-based 
assays. 
 
RNase H active site chelating agents have been reported since 2005 as promising RNase H 
inhibitors (Tramontano et al. 2005). However, the lack of improvements in potency of inhibition, 
together with information coming from crystal structures of RNase H domain interacting with 
active site inhibitors bound in an orientation unfavorable for ligand optimization, dejected 
pharmaceutical companies and academia from further research in that direction. In the absence of 
crystal structure information of HIV-1 RNase H domain with our DKA inhibitors, we  considered the 
high similarity between HIV-1 and Foamy virus prototype (FV) RTs. Given the recent resolution via 
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NMR of the FV RT we decided to use it as a tool to explore the mechanism of action of known 
RNase H inhibitors. We  characterized  the mode of binding of inhibitors active against FV RT by 
NMR analysis to acquire information about their binding sites. With opportune comparative 
structural analysis this information was then translated to the HIV-1 RNase H domain, and 
confirmed by docking on HIV-1 RT and site directed mutagenesis to identify and characterize 
residues involved in binding. The DKA selectivity for the target has been evaluated both in 
biochemical assays and in cell culture assays. 
 
Dual allosteric inhibitors of both RNase H and RDDP are a fascinating possibility to overcome the 
rapid selection of viral strains resistant to the currently approved single target drugs. Until now, 
none of the approved antiviral drugs is active on both functions, although a number of compounds 
have been reported to inhibit both RT functions in vitro(Distinto et al. 2013), and two binding sites 
located in different areas of the enzyme have been reported and hypothesized: the first one near 
the polymerase active site, the second one close to the RNase H active site. A recent virtual 
screening campaign conducted by our group has identified a promising isatine-derived scaffold 
active on both functions in the low micromolar range (Distinto et al. 2012). In this thesis I have 
explored the possibilities of binding of a newly synthetized isatine-derivative into the whole HIV-1 
RT using a blind docking experiment and site directed mutagenesis that confirmed and 
characterized the in silico outcomes. I identified two indipendent binding pockets and I looked for 
an exhaustive explanation of this singular mechanism of inhibition, in the attempt to discriminate 
between the respective role of the two pockets involved.  
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Chapter 2. 
Material and Methods 
 
2.1 Prototype Foamy Virus Reverse Transcriptase  
2.1.1 Protein purification.  
Purification of PFV PR-RT and 15N labelled PFV RNase H was performed as described previously 
(Hartl et al. 2010; Leo, Schweimer, et al. 2012).  
 
2.1.2 PFV RT DNA polymerase-independent RNase H activity determination.  
The PFV RT-associated RNase H activity was measured in 100 µL reaction volume containing 50 
mM Tris HCl pH 8.1, 6 mM MgCl2, 1 mM dithiothreitol (DTT), 80 mM KCl, hybrid RNA/DNA (5’-
GTTTTCTTTTCCCCCCTGAC-3’-Fluorescein, 5’-CAAAAGAAAAGGGGGGACUG-3’-Dabcyl) and 2 nM 
PFV RT. The reaction mixture was incubated for 1 hour at 37°C, the reaction was stopped by 
addition of EDTA and products were measured with a Victor 3 (Perkin) at 490/528 nm. 
 
2.1.3 PFV RNA dependent DNA polymerase activity determination. 
 The PFV RT-associated RNA-Dependent DNA Polymerase (RDDP) activity was measured in 50 µL 
volume containing 60 mM Tris‐HCl pH 8.1, 8 mM MgCl2, 60 mM KCl, 13 mM DTT, 100 µM dTTP, 5 
nM PFV RT and poly(A)-oligo(dT) (EnzCheck kit Invitrogen). The reaction mixture was incubated for 
30 min at 37°C. The enzymatic reaction was stopped by addition of 50µl of 0.5M EDTA pH 8.0. 
Reaction products were detected by picogreen addition and measured with a Victor 3 (Perkin) at 
502/523 nm (excitaion/emission wavelength). 
 
2.1.4 NMR analyses. 
 Standard NMR HSQC experiments were recorded using 50 - 80 µM 15N PFV labelled RNase H in 
5mM Na-phosphate pH 7.0, 100 mM NaCl, 6 mM MgCl2, 0.5 mM DTT, 10% D2O (v/v), 6 % 
deuterated DMSO at 25°C on Bruker Avance 700 and 800 MHz spectrometers partially equipped 
with a cryogenically cooled probe. In-house protocols were used to process the NMR data and the 
program NMRView was utilized for analysis (B.A. Johnson, Merck, Whitehouse Station, NJ, USA). 
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Inhibitors were dissolved in 100% deuterated DMSO to a final concentration of 100 mM and added 
at the concentrations indicated in the Results section. Control HSQC spectra of PFV RNase H at 
various concentrations of deuterated DMSO were recorded for each titration step. Final DMSO 
concentrations for RDS1643 did not exeed 11%.  
Changes in the chemical shifts were expressed by calculating the weighted geometric average 
(equation 1, c15N = 0.1) of chemical shifts of 
1H and 15N spins. A chemical shift change with a 
weighted geometric average of greater or equal 0.02 ppm was considered as significant. 
equation 1:           √    
                 
 
2.2 HIV-1 Reverse Transcriptase 
2.2.1 Site-directed Mutagenesis. 
RTs strains naturally resistant to NNRTIs (K103N, Y181C, Y188L) have missence mutations on both 
p66 and p51 enzymatic subunits. Amino acid substitutions were introduced in both p51 and p66 
subunits by mutating the RT wt gene coded together with the protease gene  in a p(His)6-tagged 
p66/p51 HIV-1HXB2 RT-prot Mutagenesis was realized using the QuikChange protocol(Agilent 
Technologies Inc., Santa Clara, CA). The plasmids were kindly provided by Stuart Le Grice 
Laboratory (NCI Frederick).  
In the mutants RTs realized for binding characterization purposes  the mutations were selectively 
introduced in the p66 subunit only. 
Amino acid substitutions in the RT p66 RNase H domain (R448A, N474A, Q754A, Y501A, A502F, 
A508V, R557A) were selectively introduced mutating the RT wt gene coded together with the 
protease gene in the p6HRT-prot plasmid. Since all mutated residues are located in the RNase H 
domain, and because of proteolytic events ocurring after expression delete the RNase H domain 
from the resulting p51, this leads to  mutated p66/ wt p51  RT heterodimers. 
 
Aminoacid substitution in the RT p66 polymerase domain (V106A, V108A, Y188A, E224A, P225A, 
P226A, F227A, L228A, W229A, M230A, G231A). Aminoacid substitutions were introduced 
selectively into the only p66 subunit of HIV-1 RT coded in a p66RT plasmid (not His-tagged) . RTs  
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with mutated p66/ wt p51 were obtained co-purifing mutated p66 together with His-tagged wt 
p51 after separate expression.  
 
2.2.2 Protein  expression and purification . 
Heterodimeric wt RT, NNRTI resistant RTs and mutant RTs containing amino acid substitutions in 
the RNase H domain only were expressed essentially as described (Le Grice et al., 1995). 
Monomeric subunits of recombinant RTs containing mutation in the p66 polymerase domain only 
were expressed separately (p66 and p6H51) using the same protocol. 
 Briefly, E. coli strain M15 containing the pRT-prot or vector, wt or mutated, were grown up to an 
OD600 of 0.7 and induced with 1.7 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) for 4 h. SDS-
PAGE  followed by Coomassie staining was used to verify the final product of expression. 
Lysis protocol:cell pellets were resuspended in Lysis buffer (50 mM Sodium Phosphate pH 7.8, 0.5 
mg/mL lysozyme), incubated on ice for 20 min, added 0.3 M final NaCl, sonicated and centrifuged 
at 30,000×g for 1 h. The supernatant was recovered for protein purification. In the case of p66 
polymerase domain mutants the pellet containing p66RT expression was combined in an equal 
ratio with pellet of expression of p6H51 (his-tagged wt subunit) before the lysis and the 
supernatant was gently stirred overnight at 4°C to allowheterodimer reconstitution. 
 Protein purification was carried out with an BioLogic LP (Biorad) with a combination of 
Immobilized Metal Ion Affinity Chromatography and Ion Exchange chromatography.The 
supernatant was loaded onto a Ni2+-sepharose column pre-equilibrated with Loading Buffer (50 
mM Sodium Phosphate pH 7.8, 0.3M NaCl, 10% glycerol, 10 mM imidazole) and washed 
thoroughly with Wash Buffer (50 mM Sodium Phosphate pH 6.0, 0.3 M NaCl, 10% glycerol, 80 mM 
imidazole). RT was gradient-eluted with Elute Buffer (Wash buffer with 0.5 M imidazole). Fractions 
were collected, protein purity was checked by SDS-PAGE and found to be higher than 90%. 
Enzyme-containing fractions were pooled and diluted 1:1 with Dilute Buffer (50 mM Sodium 
Phosphate pH 7.0, 10% glycerol) then loaded onto a Hi-trap Heparine HP GE (Healthcare 
lifescience) pre-equilibrated with 10 column volumes of Loading Buffer 2 (50 mM Sodium 
Phosphate pH 7.0, 10% glycerol, 150 mM NaCl). The column was then washed with Loading 
Buffer2 and RT was gradient eluted with Elute Buffer 2 (50 mM Sodium Phosphate pH 7.0, 10% 
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glycerol, 150 mM NaCl). The fractions were collected, the protein was dialyzed and stored in 
Buffer containing 50 mM Tris HCl pH 7.0, 25 mM NaCl, 1mM EDTA, 50% glycerol. Protein 
concentration was determined by BSA Standard curve. Enzyme-containing fractions were pooled 
and aliquots were stored at −80 ◦C. 
 
2.2.4 HIV-1 DNA polymerase-independent RNase H activity determination.  
The wt and mutant HIV RT-associated RNase H activity was measured in 100 µL reaction volume 
containing 50 mM Tris HCl pH 7.8, 6 mM MgCl2, 1 mM dithiothreitol (DTT), 80 mM KCl, hybrid 
RNA/DNA (5’-GTTTTCTTTTCCCCCCTGAC-3’-Fluorescein, 5’-CAAAAGAAAAGGGGGGACUG-3’-
Dabcyl). Enzyme catalytic activities were determined via dose-response curve, in presence of 
incresing amount of enzyme: 0.9ng, 1.87 ng, 3.75 ng, 7.5ng, 15ng, 30 ng, 60 ng, 120ng,240ng, 480 
ng, 1 µg, 2µg. Different amount of enzymes according to a linear range of dose-response curve 
were used for experiments of RNase H function inhibition: 20 ng of wt RT;  60 ng K103N; 37.5 ng 
V106A; 75 ng V108A;  5 ng Y181C; 50 ng Y188A; 30 ng Y188L; 100ng E224A; 37.5 ng P225A; 20 ng 
P226A; 18 ng F227A; 30ng L228A; 30 ng W229A;  10 ng M230A; 30 ngG231A; 37.5 ng R448A; 62.5 
ng N474A;  300 ng Q475A; 1 µg Y501A; 100ng A502F; 37.5 ng A508V; 75 ng R557A.  The reaction 
mixture was incubated for 1 h at 37 °C, the reaction was stopped by addition of 0.5M EDTA pH 8.0 
and products were measured with a Victor 3 (Perkin) at 490/528 nm (excitaion/emission 
wavelength).  
 
2.2.5 HIV-1 RNA-dependent DNA polymerase activity determination. 
The HIV-1 RT-associated RNA-Dependent DNA Polymerase (RDDP) activity was measured in 25 µL 
volume containing 60 mM Tris‐HCl pH 8.1, 8 mM MgCl2, 60 mM KCl, 13 mM DTT, poly(A)-oligo(dT), 
100 µM dTTP. Enzyme catalytic activities were determined via dose-response curve, in presence of 
incresing amount of enzyme: 0.9ng, 1.87 ng, 3.75 ng, 7.5ng, 15ng, 30 ng, 60 ng, 120ng,240ng, 480 
ng, 1 µg, 2µg. Different amount of enzymes according to a linear range of dose-response curve 
were used for experiments of RDDP  function inhibition: 6 ng wt RT; 30 ng K103N RT; 12 ng V106A 
RT; 19 ng V108A RT;  1,5 ng Y181C RT; 45 ng Y188A RT; 15 ng Y188L RT; 30 ng E224A RT; 15 ng 
P225A RT; 18 ng P226A RT; 23 ng F227A RT; 15 ng L228A RT; 30 ng W229A RT;  30 ng M230A RT; 
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15 ng G231A RT;30 ng R448A, 30 ngN474A, 100ng Q475A, 30ng Y501A, 15 ng A502F RT; 19 ng 
A508V RT; 30 ng R557A RTs. After enzyme addition the reaction mixture was incubated for 30 min 
at 37 °C and enzymatic reaction was stopped by addition of 2µl of 0.2M EDTA pH 8.0. Reaction 
products were detected by picogreen addition and measured with a Victor 3 (Perkin) at 502/523 
nm (excitaion/emission wavelength). 
 
2.2.6 Evaluation of DNA polymerase-independent RNase H and RDDP kinetic efficiencies.  
Kinetic analyses of the DNA-polymerase independent RNase H and RDDP activities were 
performed according to Lineaweaver–Burke plots using the Sigmaplot11.0 software. Velocity (ν) 
was expressed as fmoles/min. 
 
2.2.7 Yonetani-Theorell 
Yonetani-Theorell analisys was carried out according to Yonetani (Yonetani 1982). Briefly RDDP 
reaction velocity was measured following the RDDP  function inhibition experimental protocol at 
several fixed concentrations of the inhibitor I1 RMNC6 (1.25 μM; 2.5 μM; 5 μM) while titrating the 
second inhibitor  I2 EFV (4 nM; 8 nM; 16 nM). Reaction products were measured with a Victor 3 
(Perkin) at 502/523 nm (excitaion/emission wavelenght). The reciprocal of velocity (1/v) was 
plotted as a function of concentration for RMNC6. The interaction constant α was calculated  
according to the Yonetani Theorell equation (Yonetani 1982). 
 
2.2.9 Detection of protein inhibitor interactions by Differential Scanning Fluorimetry (ThermoFluor).  
Thermal stability assays were performed according to Nettleship et al.2008 (Nettleship et al. 
2008). To a LightCycler 480 96-well plate (Roche) 1 μL of 500 μM inhibitor in DMSO was added, 
followed by 49 μL of 300 nM HIV-1 RT in reaction buffer containing 20 mM HEPES, pH 7.5, 10 mM 
MgCl2, 100 mM NaCl, and a 1:1000 dilution of Sypro Orange dye (Invitrogen). The mixture was 
heated from 30 to 90°C in increments of 0.2°C every 5 seconds. Fluorescence intensity was 
measured using excitation and emission wavelengths of 483 and 568 nm, respectively. Changes in 
protein thermal stability (ΔTm) upon inhibitor binding were analyzed by using LightCycler 480 
software. All assays were performed in triplicate. 
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2.3 HIV-1 Integrase  
2.3.1 Protein expression and purification  
HIV-1 IN was expressed essentially as reported in (Zamborlini et al. 2011). Briefly, His-tagged IN 
was produced in E. coli BL21-CodonPlus (DE3)-RIPL (Agilent, Santa Clara, USA) and purified under 
nondenaturing conditions. Protein production was induced at an OD600 of 0.6 to 0.8, by adding 
IPTG to a concentration of 0.5 mM. Cultures were incubated for 3 h at 37°C and then centrifuged 
20 min at 1100 g, 4°C. Cells were resuspended in buffer A (50 mM Tris-HCl (pH 8), 1 M NaCl, 4 mM 
β-mercaptoethanol) and lysed by passage through a French press. The lysate was centrifuged (30 
min at 12,000xg at 4 °C), and the supernatant was filtered (pore size 0.45 μM) and incubated with 
nickel-nitrilotriacetic acid agarose beads (Qiagen, Venlo, The Netherlands) for at least 2 hours at 4 
°C. The beads were washed with buffer A and then with buffer A supplemented with 80 mM 
imidazole. His-tagged proteins were then eluted from the beads in buffer A supplemented with 1 
M imidazole and 50 μM zinc sulfate. They were then dialyzed overnight against 20 mM Tris-HCl 
(pH 8), 1 M NaCl, 4 mM β-mercaptoethanol and 10% glycerol. Aliquots of the purification products 
were rapidly frozen and stored at -80°C. 
 
2.3.2  HIV-1 integrase activity. 
Strand transfer reaction was performed as described previously (Delelis et al. 2007). 
Oligonucleotides (ODN) HIV-1B (5’-TGTGGAAAATCTCTAGCA-3’) and HIV-1A (5’-
ACTGCTAGAGATTTTCCACA-3’) were used for the strand transfer-reaction. ODNs were purchased 
from Eurogentec (Liege, Belgium) and further purified by electrophoresis in a denaturing 18% 
acrylamide/urea gel. HIV-1B was radiolabelled with T4 polynucleotide kinase (Biolabs) and 
γ[32−P]ATP (3000 Ci/mmol) (Amersham), and purified on a Sephadex G-10 column (GE 
Healthcare). Double-stranded ODNs were obtained by mixing equimolar amounts of 
complementary strands (HIV-1A) in the presence of 100 mM NaCl. Strand-transfer reactions were 
carried out at 37°C, in a buffer containing 10 mM HEPES (pH 7.2), 1 mM DTT, 7.5 mM MgCl2 or 
MnCl2 in the presence of 12.5 nM DNA substrate. Products were separated by electrophoresis in 
denaturing 18% acrylamide/urea gels. Gels were analysed with a Molecular Dynamics STORM 
phosphoimager and quantified with Image Quant™ 4.1 software.  
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2.3 Cells and viruses. 
2.3.1 Viral replication titration 
MT4 and 293T cells were cultured in RPMI1640 and DMEM medium, respectively. Both mediums 
were supplemented with 10% fetal calf serum. HIV-1 stocks were prepared by transfecting 293 T 
with the HIV-1 molecular clone derived from pNL4-3 (Δenv viruses)(Gelderblom et al. 2008) Δenv 
viruses NLENG1-ES-IRES WT encode the WT integrase. Pseudotyping of Δenv viruses was 
performed by co-transfection of 293 T cells with a VSV-G plasmid using the calcium phosphate 
method. Viral supernatants were filtered (0.45 μm) after 30 min of centrifugation at 4500 g  and 
frozen at −80°C. HIV-1 p24gag antigen content in viral supernatants was determined by enzyme-
linked immunosorbent assay (Perkin-Elmer Life Sciences). For infection were used 120 ng of 
p24gag antigen per 106 cells, corresponding to a multiplicity of infection (m.o.i.) of 0.3. When 
required, cells were treated in the presence of integrase inhibitor RAL (100 nM) or efavirenz (100 
nM). Flow cytometry analysis was performed on a FACSCalibur flow cytometer (BD Bioscience) to 
meseasure cell viability and percentage of infected cells. Results were analysed using the 
ImageQuant software.  
 
2.3.2. MTT cytotoxicity assay.  
MT4 cell proliferation was measured by seeding 1x104 cells/well in 96-well plates in 100 μL of 
RPMI/FBS (10%), penicillin (100 U/mL), streptomycin (200 μg/mL). Cells were treated with 
increasing concentration of different inhibitors and subjected to MTT assay after 48 hours of 
grouth. Briefly, after discarding the supernatant, 100 µL of MTT dilution (5 mg/mL in DMEM 10% 
FBS) were added and cells were incubated for 2 hours at 37°C 5% CO2. Then, after addition of 100 
µL of Lysis Solution (20 mM HCl, 0.1% SDS), cells were incubated for 2 hours.  100 µL of final 
solution of each sample was then transferred to a new 96-well plate for quantification on a plate–
reader Spectramax at 570 nM. 
 
2.3.3 Quantification of viral DNA genomes. 
 Quantitative PCR (qPCR) was performed as described previously (Munir et al. 2013). Briefly, MT4 
cells were infected and treated with inhibitors at time zero and 10 hours post infection. RDS1759 
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and RDS1760 inhibitors were used at concentration of 10 µM, and known inhibitors Raltegavir and 
Efavirenz were used as a control at a concentration of 200 nM and 100 nM, respectively. Two to 
five millions cells were collected at each time point. Cells were washed in PBS, and dry cell pellets 
were frozen at -80°C until use. DNA from infected cells was purified using a QIAamp DNA Blood 
mini kit (Qiagen) according to the manufacturer’s instructions. Quantifications of total viral DNAs, 
2-LTRc and integrated DNAs were performed on a Light cycler instrument (Roche Diagnostics) 
using the second-derivative-maximum method provided by the Light Cycler quantification 
software, version 3.5 (Roche Diagnostics). Amplification of the β-globin gene (two copies per 
diploid cell) was performed to normalize the results using commercially available materials 
(Control kit DNA; Roche Diagnostics). The quantification results for two-LTR circle, total HIV-1 DNA, 
and integrated HIV-1 DNA were expressed as copy numbers per µg DNA. 
 
2.4 Molecular Modeling  
2.4.1 Molecular modeling on FVRT.  
Docking experiments were performed using the program AutoDock Vina (Trott & Olson 2010). 
Non-polar hydrogen atoms were removed from both protein and ligand and saved in a pdbqt 
format. A grid box was set. with 20*36*28 points in x, y , z directions and -8.5, -18, 7 as the grid 
center for PFV RNase H (PDB ID: 2LSN). The grid box included the active site residues and the 
adjacent residues exhibiting significant chemical shift changes. These parameters were saved in a 
configuration text file (config.txt) followed by autodocking. The results generated were visualized 
in PyMOL. Among the inhibitor binding orientations obtained the orientation fitting best to the 
NMR data was chosen.  
 
2.4.2 Molecular Modeling on HIV-1 RT  for DKAs binding study 
Ligands preparation: the DKAs three dimensional structures were generated with the Maestro 
Build Panel (Anon n.d.) and were then submitted to Polak-Ribiere conjugate gradient minimization 
(0.0005 kJ/(Å mol) convergence using MacroModel (version 9.9) (Anon n.d.). Ligands were 
modeled in their enolate form, since such compounds mainly exist in their enolic form in solution 
(Maurin et al. 2004)  and also given the influence of the two metal cations in the binding site. 
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Protein preparation: for docking we selected the crystal structure of the full-length HIV-1 RT in 
complex with a naphthyridinone inhibitor bound to the RNase H active site (PDB ID: 3LP1). The 
missing residue R557, which is part of the RNase H active site, was modeled using the coordinates 
of the PDB ID: 3K2P crystal structure (structure of HIV-1 RT with the inhibitor beta-thujaplicinol 
bound at the RNase H active site). The receptor was prepared using the “Protein Preparation 
Wizard” panel of Schrödinger 2012 molecular modeling package (Anon n.d.). The bond orders and 
disulfide bonds were assigned, all hydrogen atoms were added, and all water molecules deleted. 
An optimization of the hydrogen-bonding network was performed using the “H-bond assignment” 
tool. Finally, using the “impref utility”, the positions of the hydrogen atoms were optimized by 
keeping all the heavy atoms in place. 
Docking calculations: docking studies were carried out with Glide v. 5.8 (Schrödinger)(Anon n.d.). 
Glide is a grid-based ligand docking program with energetics approach and searches for favorable 
interactions between ligands and receptors. The shape and properties of the receptor are 
represented on a grid by different sets of fields that provide progressively more accurate scoring 
of the ligand position. These fields are generated as preprocessing steps in the calculation and 
hence need to be computed only once. For the grid generation, a box centered on the active site 
Mg2+ ions was created. This box gives a more precise measure of the effective size of the search 
space. However, ligands can move outside this box during grid minimization. The Cartesian 
coordinates of the outer box, X, Y, and Z lengths were each set to 20 Å. The conformational space 
of the ligand is defined by Glide by several lowest-energy poses that are subjected to a Monte 
Carlo procedure that examines nearby torsional minima. This procedure is needed in some cases 
to properly orient peripheral groups and occasionally alters internal torsion angles. The default 
value (1.00) for the van der Waals radii scaling factor was chosen, which means no scaling for the 
nonpolar atoms was performed. In the present study, the standard precision (SP) mode of 
GlideScore function was used to score the obtained binding poses. The force field used for the 
docking was the OPLS-2005  (Jorgensen et al. 1996).All of the pictures were rendered with pymol 
(www.pymol.org). 
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2.4.2 Molecular Modeling on HIV-1 RT for RMNC6 binding study 
Ligand preparation: a theoretical 3D model of RMNC6 was built using Maestro.( Schrödinger LLC., 
Maestro GUI, New York, NY, USA, 2012.) The inhibitor structure was optimized by means of an 
energy minimization carried out using the MMFFs force field  (T. Halgren, J. Comput. Chem. 1996, 
17(5-6), 520-552), the GB/SA (Hasel et al. 1988) water implicit solvation model and the Polak-
Ribier Coniugate Gradient (PRCG) method, converging on a gradient with a threshold of 0.05 
kJ(mol*Å)-1. 
Protein preparation: the coordinates for reverse transcriptase enzymes were taken from the RCSB 
Protein Data Bank (Berman et al. 2000) (PDB codes 1vrt (Ren et al. 1995), 2zd1 (Das et al. 2008), 
1ep4 (Ren 2000), 3qo9 (Das et al. 2011), 1rti (Ren et al. 1995) 1tv6 (Pata et al. 2004) , 3lp2 
(Himmel et al. 2009). The proteins were prepared using the Maestro Protein Preparation Wizard. 
Original water molecules were removed and termini were capped. The bond orders and formal 
charges were added for hetero groups, and all the hydrogen atoms were added in the structure. 
Missing hydrogens atoms were included. After preparation, the structures were refined in order to 
optimize the hydrogen bond network using OPLS_2005 (Kaminski et al. 2001) force field. The 
minimization was terminated when the energy converged or the RMSD reached a maximum cut-
off of 0.30 Å.  
Docking protocol: molecular docking studies were performed using the QMPL workflow protocol.( 
Schrödinger LLC., QMPolarized protocol, in Schrodinger Suite, New York, NY, USA). Grids were 
defined around the refined structure by centering on the residue W229 (located in the NNRTI 
binding pocket) and Q500 (located in the RNase H domain) and fixing the box volume at 97,336 Å3, 
covering the whole p66 and most of p51 subunit. The extra precision (XP) docking algorithm was 
applied for scoring theoretical poses. The other settings were left as default. The same protocol 
was applied to all simulations. 
Post docking protocol: 10,000 steps of the Polak-Ribier conjugate gradient (PRCG) minimization 
method were conducted on the top ranked theoretical complexes using OPLS_2005 force field. 
The optimization process was performed up to the derivative convergence criterion equal to 0.01 
kJ/(mol*Å)-1.The binding free energies (ΔG(Bind)) were computed applying molecular mechanics 
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and continuum solvation models with the molecular mechanics generalized Born/surface area 
(MM-GBSA) method (Kollman et al. 2000).  
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Chapter 3.  
Foamy virus reverse transcriptase as a tool to characterize 
human immunodeficiency virus type 1 ribonuclease H 
inhibitors  
 
 
3.1 Introduction 
The retroviridae family is divided into two major subfamilies: the orthoretrovirinae, including α to ε 
and lentiviruses, and the spumaretrovirinae, and one more that include the only genus of FVs 
(Linial 2007). FVs differ from orthoretrovirinae in many aspects of the retroviral replication cycle, 
e.g. reverse transcription takes place before the virus buds from the host cell, so that DNA is found 
in extracellular FV particles,  similar to hepadnaviruses (Yu et al. 1996). Moreover, in FVs only the 
IN is cleaved off from the Pol precursor, leading to a mature, multifunctional protease-RT (PR-RT) 
enzyme in the virus particle. In contrast, all other retroviruses – including HIV-1 – cleave off the PR 
domain from Pol (Pfrepper et al. 1998; Roy & Linial 2007). 
Therefore, in FVs, the mature PR-RT carries out the functions of the PR and the RT, including the 
RT-associated RDDP and RNase H activities (Rinke et al. 2002; Boyer et al. 2007; Hartl et al. 2010). 
A few studies have characterized the enzymatic properties of prototype FV (PFV) PR-RT, 
particularly in comparison with the HIV-1 RT, showing that PFV PR-RT-associated RDDP activity is 
more processive than HIV-1 RT (Hartl et al. 2011); it has the same fidelity as HIV-1 RT (Boyer et al. 
2007), while its KM values for dNTPs are 5-30 fold lower than the one of HIV-1 RT (Boyer et al. 
2004). Overall, these differences in the polymerization properties appear to reflect the ability of 
FVs to replicate only in dividing cells (with high dNTPs concentrations). PFV PR-RT has been shown 
to be monomeric and able to catalyze all RT related functions (Boyer et al. 2004), while PR 
activation requires dimer formation of the PR domain via binding of PR-RT to a specific element on 
the viral RNA, called PARM (protease activating RNA motif) (Hartl et al. 2010). Hence, for the 
retrotranscription functions PFV PR-RT differs from alpharetroviral and lentiviral RTs (including 
HIV-1 RT) that are dimeric, and is similar to the gammaretroviral RTs that are monomeric 
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(Herschhorn & Hizi 2010). In addition, the PFV RNase H domain possesses a basic protrusion, 
including a basic loop and the so-called C-helix, which has been proposed to be important for 
activity and substrate binding and is absent from the HIV-1 RNase H domain (Leo, Hartl, et al. 
2012; Leo, Schweimer, et al. 2012; Esposito et al. 2012).  
However, despite this, comparison of the structural features of the PFV RNase H domain with the 
HIV-1 RNase H domain, showed that they are highly similar (Leo, Schweimer, et al. 2012). In fact, 
superimposition of the two RNase H domains showed a good structural alignment, in particular in 
the domain portion that makes contacts with the hybrid substrate (Fig. 12). Therefore, we asked 
whether the PFV RNase H domain could be used as tool to investigate the interactions between 
RHIs and the RNase H domain. 
 
Figure 12  Superposition of PFV- RT and HIV-1 RT RNase H domains.PFV (blue) (PDB ID: 2LSN) and 
HIV-1 (green) (PDB ID: 1HYS) (Leo, Schweimer, et al. 2012) 
 
3.2 Inhibition of PFV PR-RT enzyme activities by RHIs 
To verify this hypothesis, we first tested the effect of known HIV-1 RT RHIs on both the PFV RT and 
HIV-1 RT RNase H and RDDP activities. In particular, we chose to test the DKA derivative RDS1643 
(Tramontano et al. 2005), the 3-hydroxy-4-propionyl-3,4-dihydroquinolin-2(1H)-one (DHQ) 
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(Suchaud et al. 2012), the natural product β-Thujaplicinol (BTP) (Chung et al. 2011), all of wich are 
chelating agents. Among the allosteric RHIs we chosen the VU urea derivative 2-amino-4,5,6,7-
tetrahydrobenzo[b]thiophene-3-carboxamide (VU6) (Chung et al. 2010), and the 
hydrazonoindolin-2-one derivative (Z)-3-(2-(4-(3,4-dihydroxyphenyl)thiazol-2-yl)hydrazono)indolin 
-2-one (NSC657589) that was shown to inhibit both, HIV-1 RT-associated RDDP and RNase H 
activities, possibly by binding to a site located in a region between the polymerase catalytic 
aspartate triad (Asp110, Asp185, Asp186) and the NNRTI pocket, hence contiguous to the NNRTI 
pocket but different from it (Distinto et al. 2012)(fig. 13).  
When these HIV-1 RHIs were tested on PFV PR-RT in biochemical assays using the methods 
previously described for HIV-1 RT-associated RNase H and polymerase functions (Distinto et al. 
2012) and the reaction conditions previously optimized for PFV PR-RT (Hartl et al. 2010), we 
observed that all selected RHIs inhibited the PFV PR-RT (Fig. 13). In particular, the metal chelating 
catalytic site binder RHIs, RDS1643, DHQ and BTP inhibited the PFV PR-RT RNase H activity with 
IC50 values comparable to the ones obtained for HIV-1 RT, with the exception of DHQ, which was 
2.5-fold less potent on PFV PR-RT than on HIV-1 RT. Unexpectedly, while RDS1643 and DHQ have 
both been reported to be selective for the HIV-1 RNase H function (Table 1), they also inhibited 
the PFV PR-RT associated RDDP activity with the same potency shown for the RNase H function 
(Figure 2). In contrast, BTP did not inhibit the RDDP activity of either enzyme (Table 1, Figure 13).  
 
 
Figure 13.  Chemical structures of HIV-1 RHIs. 
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Table 1. PFV PR-RT inhibition by HIV-1 RT RHIs 
 
PFV PR-RT HIV-1 RT 
Compound 
aRNase H 
IC50 (µM) 
bRDDP           
IC50 (µM) 
aRNase H 
IC50 (µM) 
bRDDP            
IC50 (µM) 
     
RDS1643 7.6 ± 2.0 5.2 ± 0.5 8.0 ± 1.5 > 100 
DHQ 41 ± 8 41 ± 12 16 ± 4.0 > 100 
BTP 0.3 ± 0.1 > 100 0.22 ± 0.03 > 100 
VU6 6.5 ± 0.4 15.2 ± 1.8 18.7± 4.8 > 100 
NSC657589 1.7 ± 0.3 2.0 ± 0.5 4.4 ± 1.3 7.4 ± 1.7 
Efavirenz > 20 > 20 > 20 0.015 ± 0.005 
                              a
Compound concentration required to inhibit RT-associated RNase H activity by 50%.  
                             b
Compound concentration required to reduce RT-associated RDDP activity by 50%.  
 
 
Figure 14. Dose dependent PFV PR-RT inhibition by HIV-1 RHIs. PFV PR-RT associated RNase H (•) 
and RDDP (o) activities were assayed at 37 °C as described for 1 hour (RNase H) and 30 minutes 
(RDDP) in the absence and in the presence of different concentration of RDS1643 (Panel A); β-
Thujaplicinol (Panel B); VU6 (Panel C); NSC657589 (Panel D). Results represent averages and 
standard deviations of three independent experiments. 
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Next we assayed the VU derivative VU6, showing that it inhibited the PFV PR-RT associated RNase 
H function 2.9-fold more potently than the HIV-1 RT. Interestingly, VU6 was also able to inhibit the 
PFV PR-RT associated RDDP activity, while it was inactive on the HIV-1 RT RDDP (Table 1). 
Subsequently, we tested the hydrazonoindolin-2-one derivative NSC657589 that has been  
reported previously to inhibit both HIV-1 RT associated functions (Distinto et al. 2012). Our data 
reveal that this compound also inhibited both PFV PR-RT RNase H and RDDP functions. However, 
the IC50 values observed for PFV PR-RT inhibition by NSC657589 were 2 to 3-fold lower than the 
ones observed for HIV-1 RT inhibition.  
 
3.3 Effect of the NNRTI EFV on the PFV PR-RT enzyme activities 
Given the ability to inhibit the PFV RT-associated RDDP activity shown by the tested RHIs, we 
asked whether the NNRTI EFV was also able to inhibit the PFV PR-RT functions. It is worth to note 
that it is known that the NNRTI binding pocket is present only in HIV-1 RT but not in the highly 
homologous HIV-2 RT (30) and that the HIV-1 RT tyrosines, Y181 and Y188, close to the active site 
motif Y183MDD (…VIY181QYMDDLY188V…) as well as the mutation K103N are involved in EFV 
resistance (30). Sequence comparisons show that in PFV RT only the tyrosine corresponding to 
Y188 is present (…NVQVYVDDIY317L…), however, due to the low sequence identity (ca. 26 %) it is 
difficult to judge whether the lysine corresponding to K103 is present in PFV RT. Results showed 
that EFV was not able to inhibit either PFV PR-RT functions (Table 1) confirming that the NNRTI 
binding pocket is not present in PFV PR-RT and suggest that the hydrazonoindolin-2-one derivative 
NSC657589 binds to a site which is different from the NNRTI binding pocket. 
 
3.4 NMR titration experiments with PFV RNase H.  
To learn more about RNase H inhibitor binding, the binding of several of the inhibitors, namely 
RDS1643, NSC657589 and VU6, to the free PFV RNase H domain was tested in NMR titration 
experiments. An NMR spectrum correlating the resonance frequencies of chemical shifts of amide 
protons directly bonded to 15N labeled nitrogen atoms (2D [1H-15N] HSQC, heteronuclear single 
quantum correlation) allows the individual detection of peptide backbone signals. Each signal in 
the spectrum represents a single amino acid of the peptide chain and can be assigned to an 
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individual residue. Changes in the chemical environment of a magnetically active atom, e.g. 
binding of an inhibitor or ligand, lead to changes of chemical shifts of the signal. Thus, HSQC 
spectra can be used to investigate inhibitor binding.  
The structure of the PFV RNase H has previously been solved by NMR spectroscopy (PDB ID: 2LSN) 
(Leo, Schweimer, et al. 2012). Thus, NMR assignment and structural information can be used for 
inhibitor titration experiments. However, measurements using the RNase H inhibitors and PFV 
RNase H were partially hampered by the low solubility of the inhibitors in aqueous solutions and 
the high inhibitor concentrations needed in NMR spectroscopy since concentrations of 15N labeled 
enzyme of around 50 – 100 µM are necessary to obtain analyzable signals. In fact, addition of 
NSC657589 and VU6 to 15N labeled PFV RNase H resulted in partial precipitation of the inhibitors.  
Final concentrations of about 2 mM NSC657589 (ca. 32-fold excess) or 12 mM VU6 (ca. 194-fold   
excess) were added to 15N labeled PFV RNase H. However, due to partial precipitation of inhibitors 
and possibly enzyme even at lower inhibitor concentrations during the measurements, the spectra 
could not be evaluated (data not shown). In contrast, addition of the inhibitor RDS1643 (49-fold 
excess) gave rise to relevant chemical shift changes of certain residues in the HSQC spectrum (Fig. 
15, 16). A chemical shift change of 0.02 ppm or greater was considered meaningful (Fig. 15, 
Fig16A). 
Significant chemical shift changes upon inhibitor addition could be observed with residues T598, 
A614, G617, T641, I647, A648, T668, Y672, A674, W703, K722, H732 and T733. The overlays of the 
HSQC spectra of residues T641 and W703 recorded at various inhibitor concentrations are 
illustrated in Figure 15B. The data confirm that RDS1643 binds to the RNase H domain and suggest 
that effects on polymerization are indirect. However, we cannot exclude a second binding site in 
the polymerase domain.  
In Figure 17A the residues exhibiting significant chemical shift changes upon inhibitor addition are 
highlighted in the three-dimensional structure of PFV RNase H. The ribbon diagram and the 
surface representation in Figure 17B show that amongst the residues with significant chemical 
shift changes, T598, A614, G617, A648, T668 and A674 are not surface exposed, while residues, 
T641, I647, Y672 and W703 are spatially close together and oriented towards the protein surface. 
48 
 
 
 
Residues T598, I647, A648 and T668 are adjacent to the active site residues D599, E646, and D669 
respectively. W703 is in the alpha helix D, which follows the basic loop that has been shown to be 
involved in nucleic acid substrate binding (Leo, Schweimer, et al. 2012). T641 is located at the 
beginning of alpha helix A, which also harbors the active site residue E646.  
These data indicate that the inhibitor binding pocket is located next to the active site and could be 
formed by the surface exposed residues T641, I647, Y672 and W703. Residues K722, H732 and 
T733 located at the beginning of alpha helix E and the adjacent N-terminal loop are also surface 
exposed. However, they exhibited only small chemical shift changes (< 0.03 ppm), which could be 
due to minor direct or indirect conformational changes induced by the binding of the inhibitor. 
 
 
                    
Figure 15: Interaction of PFV RNase H with inhibitor RDS1643.Overlay of [1H15N] HSQC spectra of 
80 µM 15N labeled PFV RNase H in the absence (black) and presence of 3.9.mM RDS1643 (red). 
Resonances with significant changes of chemical shifts are labeled. 
49 
 
 
 
 
Figure 16. Backbone chemical-shift changes upon inhibitor binding. (A) Changes of chemical shifts 
of PFV RNase H after addition of 3.9 mM RDS1643 as a function of the primary sequence. 
Chemical-shift changes larger than 0.02 ppm, indicated by a horizontal red line, were considered 
significant. Residues that were not assigned are marked by an x on the X. axis (B). [1H 15N] HSQC 
overlays of the T641 (left panel) and W703 (right panel) amide cross peaks at each inhibitor 
titration step shown in different colors (black: 0 mM; blue: 1.0 mM; green: 2.0 mM; cyan: 3.0 mM; 
red: 3.9 mM;RDS1643) 
A 
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Most of the other residues shown in Figure 16A are located in the interior of the protein (Figure 
17B) and therefore do not come into consideration for direct inhibitor contact. Rather, binding of 
the inhibitor might lead to indirect changes in the local structure of the protein, by changing side 
chain orientations. 
 
3.5 Molecular modeling of RDS1643 on the PFV RNase H domain.  
To show how the nucleic acid substrate is bound in relation to the putative inhibitor binding 
pocket, we modeled the RNA/DNA substrate of the human RNase H/RNA/DNA complex (PDB ID: 
2QK9) onto the PFV RNase H (Leo, Schweimer, et al. 2012). For clarity, only the nucleic acid 
without human RNase H is presented. It has been shown previously by UV/Vis spectroscopy and 
isothermal titration calorimetry that RDS1643 and other DKAs chelate Mg2+ or Mn2+(Tramontano 
et al. 2005; Shaw-Reid et al. 2005) and thus may interact with the metal ions in the active site of 
RNase H. This is consistent with our observation of chemical shift changes in the NMR titration 
experiment close or next to the active site residues. Overall, these data suggest that RDS1643 can 
chelate the Mg2+ into the RNase H active site and that it can make additional interactions with 
residues next to it to stabilize its binding. To further verify this mode of interaction we performed 
docking calculations with RDS1643 and PFV RNase H using the program AutoDock Vina(Trott & 
Olson 2010). Based on our NMR data we limited the potential binding site to the active site and 
the area including residues T641, I647, Y672 and W703. 
Figure 17D depicts a possible binding mode of the inhibitor that is in good agreement with our 
results. The keto-groups of RDS1643 reach into the RNase H active site and thus may be able to 
chelate the metal ions while the hydrophobic part of the molecule is close to Y672 and W703. 
 
3.6 Structure comparison between the HIV-1 and PFV RNase H domains.  
To elucidate the binding of RDS1643 to HIV-1 RNase H, a secondary structure alignment of HIV-1 
RNase H and PFV RNase H was performed (Figure 18A). In HIV-1 RNase H residues T473, L479, 
Y501 and V518 correspond to T641, I647 Y672 and W703, in the inhibitor binding pocket of PFV 
RNase H. The structural overlay of PFV RNase H with HIV-1 RNase H presented in Figure 18B 
implies that in HIV-1 RNase H binding of the inhibitor could take place in a similar way.  
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Figure 17. Identification of the putative inhibitor binding site on the structure of PFV RNase H. 
The normalized chemical shift changes (weighted geometric average of 1HN and 15N chemical shift 
changes) are shown in the PFV RNase H. Amino acids showing significant chemical shift changes at 
an RDS1643 concentration of 3.9 mM are highlighted. Changes equivalent or larger than 0.02 ppm 
are illustrated in pink, changes larger than 0.03 ppm in violet and changes larger than 0.04 ppm 
are shown in red. The active site residues are represented in green. (A) Ribbon presentation of PFV 
RNase H (PDB: 2LSN). (B) Surface presentation of PFV RNase H highlighting the surface exposed 
residues with significant chemical shift changes.  (C) Surface presentation of PFV RNase H with an 
RNA/DNA hybrid. Based on the structure of the human RNase H/substrate complex (PDB: 2QK9) a 
structural alignment of the PFV and human RNase H was performed to model the RNA/DNA 
substrate of the human RNase H onto PFV RNase H (Rmsd: 2.35 Å) (Leo, Schweimer, et al. 2012). 
The RNA strand is shown in dark blue, the DNA strand in light blue. (D) Inhibitor modeling. RDS 
1643 was modeled onto the structure of the PFV RNase H using the modeling program AutoDock 
Vina (Trott & Olson 2010). 
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However,we have also shown that RDS1643 binding to the RNase H has different effects on the 
RDDP activity of the two enzymes (table 1). This is likely due to additional structural differences, 
i.e. heterodimer vs. monomer. 
3.7 Discussion 
To attempt to better understand the mode of action of a series of HIV-1 RT RHIs, we used the PFV 
RT as a model to gain important insights. This was possible because the structural features of HIV-
1 and PFV RNase H domain are in good agreement (Fig.12). We demonstrated that, surprisingly, 
RDS1643 and DHQ, HIV-1 RNase H active site inhibitors, are active on both PFV PR-RT DNA 
polymerase and RNase H functions, suggesting on the one hand similarity in the RNase H domains 
of the two enzymes, on the other hand differences in enzyme flexibility/dynamics. This can be 
explained by three different hypotheses. Firstly RDS1643 and DHQ may be able to chelate the 
Mg2+ ions in the PFV PR-RT DP site as well as in the RNase H active site, while BTP is not able to act 
on the DP site. However, in all the retroviral RTs crystallized so far, the geometry of the two sites is 
quite different and this hypothesis is not very likely. A second possibility is therefore more likely in 
wich binding of RDS1643 and DHQ at the PFV RNase H active site reduces the PFV PR-RT flexibility 
and, through a long-range effect, it can also affect its RDDP activity. In fact, it has been shown that 
HIV-1 RT possesses a peculiar ability to flip orientations on the nucleic acid template and that it 
has high flexibility (Liu et al. 2008)  and PFV could show a similar flexibility. It is likely, given the 
small nature of the the BTP,that the interactions with the amino acid residues in the PFV PR-RT 
RNase H site do not involve the same residues that instead interact with RDS1643 and DHQ, so 
that the long-range effect do not take place. The third possibility is that the compounds that 
inhibit both functions have two different binding sites on the PFV RT. 
Therefore, further studies on PFV PR-RT may elucidate whether the inhibition of its DNA 
polymerase activity by RNAse H active site inhibitors is due to long-range effects of compounds 
binding to the RNase H pocket, which may be stronger in a monomeric protein such as PFV PR-RT, 
or whether it is due to an intrinsic lower protein flexibility that, therefore, is more easily inhibited 
by a drug binding anywhere on the enzyme.  
Interestingly, the allosteric RHIs NSC657589 and VU6 also inhibited both FV-PR RT functions. 
NSC657589  has been proposed to inhibit HIV-1 RT by binding a site close to, but distinct from, the 
53 
 
 
 
 
Figure 18. Identification of the putative inhibitor binding pocket in HIV-1 RNase H. (A) Sequence 
and secondary structure alignment of PFV and HIV-1 RNase to identify the corresponding residues 
HIV-1 RNase H (PDB ID: 1HRH). The active site residues are highlighted in green. The four residues 
in HIV-1 RNase H that are equivalent to the ones in PFV RNase H exhibiting chemical shift changes 
at 3.9 mM RDS1643 are labeled equivalent to the colour coding in Figure 4A. (B) Structural overlay 
of the RNases H from PFV (PDB ID: 2LSN) (gray) and HIV-1 (PDB ID: 1HRH). (blue). Colour coding of 
relevant residues as in Figure 17A. 
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NNRTI binding pocket (Distinto et al. 2012), the reported results may suggest either that this 
pocket is also present in the PFV PR-RT or that the NSC657589 activity on HIV-1 RT is due to the 
binding to a different site/s, possibly close to the RNase H binding pocket.  This hypothesis is 
further corroborated by the observation that EFV was not able to inhibit either PFV PR-RT 
functions, as reported for other retroviruses with monomeric RTs (Figueiredo et al. 2006). This 
confirm that a pocket equivalent to the one of  NNRTIs is not present in PFV PR-RT, and that, 
therefore,  NSC657589 act  on RDDP function with a mechanism different from NNRTIs.  
VU6 derivatives also inhibited both PFV PR-RT functions. Vinilogous ureas have been proposed to 
inhibit HIV-1 RNase H  allosterically, by binding a pocket located at the junction between the p51 
subunit thumb subdomain and the p66 RNase H domain and, in particular, to interact with an α-
helix adjacent to the RNase H domain in the p51 subunit. It is possible that even though HIV-1 RT is 
a heterodimer and PFV PR-RT is a monomer, this pocket is present in both proteins. Therefore, the 
VU6 inhibition of both PFV PR-RT RNase H and RDDP functions seems to reinforce the hypothesis 
that the binding of RHIs to PFV PR-RT may decrease its flexibility leading to a complete loss of its 
catalytic activities. 
NMR titration experiments with FV RNase H and the inhibitor RDS1643 identified the putative 
binding site in the RNase H, located next to the PFV RNase H active site and could be formed by 
the surface exposed residues T641, I647, Y672 and W703. Sequence and structure alignments with 
HIV-1 RNase H were used to reveal the corresponding putative binding site in HIV-1 RNase H, 
suggesting that in HIV-1 RT the compound may interact with the corresponding residues T473, 
L479, Y501 and V518, some of which are higly conserved since parto of the RNase H primer grip 
motif (Rausch et al. 2002). This obstervation makes appealing the further investigation on DKA 
binding mode into HIV-1  RNase H active site, by docking of RDS1643 in the HIV-1 RT RNase H 
domain and site directed mutagenesis of the residues identified as critical for the inhibitor binding. 
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Chapter 4.  
A combined cell-based and site-directed mutagenesis 
approach defines highly conserved residues involved in the 
selective inhibition of the HIV-1 RNase H function by DKA 
derivatives  
 
4.1 Introduction 
Diketo acid (DKA) derivatives are among the first compounds reported to chelate the Mg2+ 
cofactors in the active site of influenza virus endonuclease (Tomassini et al. 1994), HIV-1 IN (Wai et 
al. 2000)i and HIV-1 RNase H (Sluis-Cremer et al. 2004; Hazuda et al. 2004; Enzo Tramontano et al. 
2005). In particular, the ester DKA derivative RDS1643 has been shown to inhibit HIV-1 RNase H in 
biochemical assays and to inhibit viral replication in cell culture (Tramontano et al. 2005). 
Recently, new DKA derivatives active against both HIV-1 IN and RNase H activities have been 
reported (Costi et al. 2013).  
NMR studies reported in chapter 3 gave important insights into the possible interactions between 
RDS1643 and HIV-1 RNase H domain. With the aim of clarifying whether the catalytic region of the 
RNase H can offer additional anchor point that could be targeted by drugs, we explored the DKAs 
molecular determinants required for the interaction with the HIV-1 RT RNase H domain and that 
are responsible for the specific RNase H inhibition while not influencing the HIV-1 IN activities. 
Starting from the DKA prototype RDS1643, we synthesized 6 couples of ester/acid derivatives by 
introducing different substituents either in the benzyl moiety or in the pyrrole ring. Biochemical 
assays revealed that such derivatives inhibit both RNase H and IN activities in the low micromolar 
range. Out of these 12 compounds, 8 also inhibited viral replication in cell culture. Subsequent 
molecular modeling studies suggested interactions between DKAs and a number of residues lining 
the enzyme active site. Guided by these studies we therefore mutated these residues into Ala, and 
biochemical assays on single mutant HIV-1 RTs allowed us to probe their involvement in DKAs 
binding. Cell based assays were then used to characterize the mechanism of action for a selected 
couple of ester/acid derivatives confirming the inhibition pattern observed in enzyme assays. In 
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summary, our data establish a well-defined interaction pattern for DKA derivatives with highly 
conserved amino acid residues in the RNase H active site. Furthermoere we show that derivative 
RDS1759 effectively inhibits HIV reverse transcription in cells, laying the foundations for further 
development of RHIs. 
 
4.2 Inhibition of HIV-1 RT-associated DNA polymerase-independent RNase H 
activity by DKAs. 
To investigate the structural features of DKAs required for binding to the RNase H active site, 
starting from the DKA prototype RDS1643 (Tramontano et al. 2005) a new series of DKAs 
derivatives were designed and synthetized by introducing different substituents either in the 
benzyl moiety or in the pyrrole ring (Fig. 19) 
These modifications were realized to specifically explore the effects on the RNase H inhibitory 
activity of i) alogens or alkylic substituents at different positions on the benzyl ring (RDS1643-
1644; RDS 1759-1760; RDS1822-1823; RDS2291-2292), ii) the shift of the diketoester chain from 
position 3 to position 2 on the pyrrole ring (RDS2400-2401; RDS1711-1712), and iii) the insertion 
of a further phenyl ring in position 4 of the pyrrole ring (RDS1711-1712). In addition, we 
synthesized each derivative both in their ester and acidic forms to evaluate whether the different 
nature of the DKA branch could modulate the activity profile of our compounds.  
The six ester/acid couples were tested for their ability to inhibit the HIV-1 DNA-polymerase 
independent RNase H function and the IN activity in biochemical assays and viral replication in 
cell-based assays (Table 2). All the newly synthetized DKAs inhibited the RNase H activity, with 
ester derivatives generally being more potent than the acidic counterparts. This effect was more 
evident for derivatives RDS1759, RDS2291 and RDS2400 that showed IC50 values for RNase H 
activity of 7.3, 8.2 and 11.2 µM respectively, whilst completely inactive as IN inhibitors. 
Conversely, in the case of HIV-1 IN, all the acid derivatives were more potent than their ester 
counterparts, as reported in a previous work (Costi et al. 2013). The different activity profile of 
ester/acid DKAs on HIV-1 RNase H and IN functions may arise from the different electrostatic 
properties of the active site of the two enzymes. In particular, in RNase H  
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Figure 19. Chemical structures of DKA derivatives 
The prototype RDS1643 is depicted in the red square. Substituents in the benzyl moiety are shown 
in red, additional phenyl ring is shown in blue, displaced diketoester chain is shown in purple. 
 
four catalytic acid residues (D443, E478, D498 and D549) completely neutralize the four positive 
charges of the two active site Mg2+ ions. On the other hand, the IN active site is positively charged 
since only three acidic residues (D64, D116, D152) counterbalance the four positive charges of the 
two catalytic Mg2+ cations. In this perspective, negatively charged acidic compounds may bind 
more favorably to HIV-1 IN than to the RNase H active site. To test this hypothesis, it was verified 
whether both ester and acid DKAs effectively chelate the Mg2+ ions in the RNase H active site. To 
this aim, the DKAs UV spectra were recorded in absence and presence of magnesium ions. The 
results showed that the maximum absorbance of each compound shifted in the presence of 6 mM 
MgCl2, confirming that both ester and acid DKAs are able to chelate Mg2+ (Fig.20-21). Finally, 
when tested on HIV-1 replication, four ester/acid couples were able to selectively inhibit viral 
replication, while couples RDS2400-2401 and RDS2291-2292 were inactive (Table 2).  
 
4.3 Molecular docking 
To elucidate the binding mode of our ester/acid DKAs at into the RNase H active site at a 
molecular level, molecular docking studies were performed. For docking the crystal structure of 
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the full-length HIV-1 RT in complex with a naphthyridinone inhibitor bound into the RNase H active 
site (PDB ID:3LP1) was selected. The missing residue R557, which is part of the RNase H active site, 
was modeled using the coordinates of the PDB ID:3K2P crystal structure of the HIV-1 RT isolated 
RNase H domain with the inhibitor β-thujaplicinol bound at the active site (see Methods for 
details). Dockings of RDS1643 and RDS1644 show that both ester and acid DKAs binds at the 
RNase H active site coordinating the two catalytic Mg2+ ions. However, docking predicts that esters 
and acids should adopt slightly different binding orientation because of the steric hindrance of the 
ethyl substituent in the ester derivatives (Fig. 22A-22B). Besides the coordination of the metal 
ions, both RDS1643 and RDS1644 were hypothesized to interact with a number of RNase H active 
site residues, some of them located in the primer grip region, with important structural and 
functional roles (Rausch et al. 2002). In particular, the diketo-ester branch of RDS1643 makes H-
bonds with the N474 side chain and establishes lipophilic interactions with the A445 and I556 
residues through its ethyl substituent (Fig. 22A), while the DKA moiety of RDS1644 forms a salt-
bridges with the R557 side chain (Fig. 22B). Additionally, the benzyl ring of both ester and acidic  
 
Table 2. Biological effects of DKA derivatives on the HIV-1 RT-associated RNase H and processing 
activities and HIV-1 replication  
 
 
Compound 
RNase H 
aIC
50 
(M) 
IN 
bIC
50 
(M) 
HIV-1 
cEC
50 
(M) 
MT4 
dCC
50 
(M) 
eSI 
RDS1643 8.6 ± 1.3 20.7 ± 3,6 15.5 >50 >3.22 
RDS1644 16.1 ± 2.3 0.16 ± 0.025 0.29 >50 >172 
RDS1711 8.0 ± 0.2 21.5  ± 12.0 4.3 26.9 6.3 
RDS1712 7.7 ± 0.5 1.55 ± 0.15 17.2 >50 >2.9 
RDS1759 7.3 ± 0.03 >100 2.10 >50 >23.8 
RDS1760 19.4 ± 0.8 0.59 ± 0.77 15.4 >50 >3,2 
RDS1822 6.3 ± 1.8 42.7 ± 28 3.4 14.1 4.14 
RDS1823 87 ± 5.1 0.59 ± 0.19 3.2 >50 >15.6 
RDS2291 8.2 ± 1.2 >100 >15.4 15.4 = 
RDS2292 19.3 ± 2.6 26.21 >25.5 25.5 = 
RDS2400 11.2 ±1.1 >100 >50 >50 = 
RDS2401 28.4 ± 5.4 27.8 >50 >50 = 
a
Compound concentration (± standard deviation) required to inhibit HIV-1 RT-associated RNase H activity by 50%.  
b
Compound concentration (± standard deviation) required to inhibit HIV-1 IN activity by 50%.  
c
Compound concentration required to decrease viral replication in MT-4 cells by 50%. 
d
Compound concentration required to reduce infected MT-4 cells viability by 50%. 
e
Selectivity index (CC50/EC50 ratio). 
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Figure 20. Effect of MgCl2 on the spectrum of absorbance of dual RTIs. 
Chelation of Mg2+ by UV–vis spectrum was measured in presence of 100 µM concentration of 
compound alone (red line) or in the presence of 6mM MgCl2 (blue line). 
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Figure 21. Effect of MgCl2 on the spectrum of absorbance of dual RTIs. 
Chelation of Mg2+ by UV–vis spectrum was measured in presence of 100 µM concentration of 
compound alone (red line) or in the presence of 6mM MgCl2 (blue line). 
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derivatives can form parallel-displaced interactions with the Y501 side chain, while the pyrrole ring 
of RDS1643 can establish further lipophilic interactions with the Cα and Cβ carbons of the 
Q475residue. Finally, docking of the ester derivative RDS1711 (Fig. 22C) indicates that this 
compound is able to form an additional cation-π interaction with the R448 guanidinium group 
through its benzyl substituent, while the phenyl at position 4 on the pyrrole ring interacts with the 
Y501 side chain (Fig. 22C). Conversely, the corresponding acid RDS1712 is not predicted to interact 
with the R448 side chain, whilst its 4-phenyl substituent interacting with the Y501 side chain and 
its N-benzyl group contacting residue W535 (Fig. 22D). 
 
Figure 22. Molecular modeling of the binding modes of DKA derivatives into the HIV-1 RNase H 
active site. Panel A, RDS1643 (yellow); Panel B, RDS1644 (orange); Panel C, RDS1711 (light green); 
Panel D, RDS1712 (dark green). The receptor is shown as purple ribbons, amino acids involved in 
ligand binding are highlighted as sticks. The active site ions Mg2+ ions are represented as magenta 
spheres. 
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4.4 Catalytic efficiency of mutant HIV-1 RTs  
Based on the interaction patterns predicted by docking calculations for the DKA derivatives, 
mutation into Ala of residues R448, N474, Q475, Y501, R557 within the p66 subunit of HIV-1 RT 
were selectively performed. However, it is important to note that N474, Q475 and Y501 residues 
are highly conserved, playing crucial structural and functional roles as part of the RNase H primer 
grip. In fact, mutations of the latter residues have been reported to drastically reduce the HIV-1 
replication rate (Julias et al. 2002) and, more generally, mutations within the RNase H primer grip 
motif can strongly affect RNase H enzymatic activity (Rausch et al. 2002). Hence, to verify whether 
the selected mutant RTs were suitable for quantitative assays, a kinetic analysis on both their 
RNase H and RDDP catalytic efficiencies was performed (Table 3, Fig. 23). Consistent with previous 
observations (Rausch et al. 2002) all the RNase H primer grip mutants showed a drastically 
reduced, but still measurable, catalytic efficiency for their RNase H activity (Table 3). Interestingly, 
results showed that, with respect to wt RT, both kcat and KM values of all mutant RTs decreased, 
with the former being more affected than the latter, showing that mutations affect more the 
efficiency of the enzyme machinery in the maximum of velocity resoect to substrate amount than 
the affinity of RT for the subtrate itself . In particular, compared to wt RT, the catalytic efficiency of  
 
Table 3. Comparison of HIV-1 wt and mutant RTs DNA polymerase independent RNase H and 
RDDP activities kinetics  
 
 RNase H  RDDP  
kcat (min
-1) KM (nM) kcat/KM  kcat(min
-1) KM (nM) kcat/KM 
Wt 112.7 ± 1.4 126.7 ± 5.0 0.89  23.11 ± 0.88 0.94 ± 0.03 24.6 
R557A 24.09 ± 2.9 40.9 ± 1.0 0.60  19.24 ± 1.48 0.94 ± 0.10 20.4 
R448A 43.9 ± 9.3 85 ± 22 0.52  14.56 ± 1.35 0.90 ± 0.01 16.1 
Q475A 10.7 ± 1.9 100 ± 11 0.11  8.44 ± 0.51 1.04 ± 0.18 8.1 
N474A 2.62 ± 0.55 30.0 ± 0.04 0.08  23.47 ± 0.88 1.19 ± .03 19.7 
Y501A 0.25 ± 0.07 29.4 ± 9.0 0.008  20.21 ± 0.3 1.34 ± 0.03 15.0 
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Figure 23. Comparison of the kinetics of polymerase-independent RNase H and RDDP activities 
of HIV-1 RT mutants. Panel A. Polymerase-independent RNase H cleavage for all HIV-1 RT mutants 
was measured in 100 µL reactions containing increasing amount of RNA/DNA hybrid substrate and 
fix amonut of enzymes. Panel B. RDDP activity was measured in 25 µL volume containing 100 µM 
poly(A)-oligo(dT), increasing concentrations of dTTP and fix amount of enzymes. The kinetic 
analysis (values reported in table 3) was performed according to Lineaweaver–Burke plot of the 
both RNase H and RDDP activities. (□) wt RT , (○) R448A RT, (Δ) N474A RT, (●) Q475A RT, (■) 
Y501A RT and (▼) R557A RT. 
 
N474A and Q475A RTs showed an almost 10-fold ratio decrease and the Y501A RT showed a 100-
fold reduction. In contrast, the kcat/KM ratio of the R448A and R557A mutants RTs showed no 
reduction. Finally, none of the mutant RTs showed sognificant changes in the RT-associated RDDP 
function comparde to wt RT, with sole exception of Q475A RT that demonstrated a 3-fold 
decrease in the RDDP catalytic efficiency. 
 
4.5 Evaluation of the effects of DKA derivatives on mutant RTs 
In order to verify experimentally the interactions individyated by computational studies between 
DKA derivatives and aminoacid residues, all studied DKA derivatives were evaluated for their 
effects on the RNase H function of all mutant RTs, using the RHI BTP as positive control (Table 4). 
Results show that the inhibitory potency towards RNase H was drastically reduced for all the DKAs 
when tested on N474A RT, confirming that the N474 amino acid residue is crucial for DKA binding. 
In the case of ester derivatives, the loss of the H-bond with the N474 side chain might explain the 
lower inhibitory activity of these compounds against the N474A mutant RT. However, the increase 
in the IC50 observed for the acidic ligands suggests  that the additional functional/structural role 
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for N474, as part of the RNase H primer grip motif, at the RNase H active site where its mutation 
to Ala impairs the geometry of the site.  
When tested on R557A RT only a moderate effect on the inhibitory potency was observed. 
Interestingly, this effect was higher for acidic derivatives than for their ester counterparts. Indeed, 
as predicted by docking calculations, acidic derivatives are able to make a salt-bridge with the 
R557 side chain in the WT RT, which cannot be established in the R557A mutant RT.  
A different behavior was observed when DKAs were assayed against Q475A RT. In fact, in this case, 
changes in the RNase H inhibition rate by ester compounds were generally higher to those 
measured for acidic derivatives. In particular, esters RDS1643, RDS1822, RDS2400, RDS1759 and 
 
Table 4. Inhibition of the HIV-1 RT-associated RNase H activity of selectively mutated p66/p51 
HIV-1 RT heterodimers by DKAs 
 
  RNase H aIC
50 
(M) 
WT R448A RT R557A RT N474A RT Q475A RT Y501A RT 
RDS1643 8.6 ± 1.3 10.9 ± 2.1 17.0 ± 2.3 79.9 ± 5.7 91.6 ± 11.8 > 100 (86%)
b 
RDS1644 16.1 ± 2.3 19.3 ± 1.6 44.9 ± 0.7 > 100 (55%) 5.5 ± 1.5 11.6 ± 5.1 
RDS1711 8.0 ± 0.2 100 ± 2 50.5 ± 4.7 >100 (100%) >100 (83%) >100 (100%) 
RDS1712 7.7 ± 0.5 8.1 ± 0.3 19.6 ± 3.8 >100 (62%) >100 (80%) >100 (80%) 
RDS1759 7.3 ± 0.03 8.6 ± 0.1 16.2 ± 3.0 89.4 ± 5.8 96.7 ± 1.4 >100 (100%) 
RDS1760 19.4 ± 0.8 20.6 ± 2.3 63.6 ± 0.7 >100 (79%) 6.3 ± 2.3 >100 (80%) 
RDS1822 6.3 ± 1.8 6.5 ± 3.5 17.4 ± 3.4 93.6 ± 9.6 71.2 ± 4.5 >100 (76%) 
RDS1823 87 ± 5.1 88.5 ± 5.7 >100 (68%) 100 ± 2 7.4 ± 1.5 6.4 ± 1.6 
RDS2291 8.2 ± 1.2 10.0 ± 2.0 20.7 ± 4.5 >100 (56%) >100 (76%) >100 (85%) 
RDS2292 19.3 ± 2.6 27.2 ± 3.2 58.4 ± 3.3 >100 (84%) 3.4 ± 0,6 >100 (100%) 
RDS2400 11.2 ±1.1 15.1 ± 2.9 25.1 ± 5.4 62.8 ± 12.0 >100 (55%) >100 (70%) 
RDS2401 28.4 ± 5.4 24.7 ± 1.8 61.6 ± 5.7 >100 (65%) 28.2 ± 4.1 29.8 ± 6.7 
BTP 0.20 ± 0.05 0.15 ± 0.02 0.22 ± 0.05 0.09 ± 0.01 0.19 ± 0.03 0.07 ± 0.005 
a
Compound concentration (± standard deviation) required to inhibit HIV-1 RT-associated RNase H activity by 50%.  
b
Percentage of enzyme activity measured in the presence of 100 µM compound concentration. 
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RDS2291 exhibited an at least 10-fold increase in the IC50 value with respect to wt RT, while their 
acidic counterparts exhibited a 3 to 5-folds increase in IC50 values, with the exception of derivative 
RDS1823 that showed an 11-fold increase in IC50 value. Indeed, according to docking results the 
Q475A mutation significantly reduces the interaction surface accessible to ester derivatives within 
the RNase H active site. Conversely, acidic derivatives are allowed to interact more tightly with the 
Y501 side chain through their benzyl group (or through the 4-phenyl substituent in the case of 
RDS1712).  
The RNase H inhibitory potencies of all ester derivatives were significantly lower, when tested on 
the Y501A RT mutant. Also their acid counterparts generally showed increased IC50 values, except 
compounds RDS1644 and RDS2401. It can be thus postulated that the Y501A mutation modifies 
the interaction pattern with the adjacent Q475 by inducing a conformational rearrangement of 
the protein binding site which can not be modeled with rigid protein docking experiments.  
The R448A mutation generally produced no effect on DKAs potency, with the exception of 
derivative RDS1711 that showed a 12-folds increase in the IC50 value. These results are in 
agreement with docking studies on RDS1711 and RDS1712 showing that the former, but not the 
latter, can establish a cation-π interaction with the R448 side chain in the WT enzyme through its 
benzyl group (Fig. 22C-22D), in agreement with the hypothesis of the different binding 
orientations of esters and acid derivatives. 
 
4.6 Characterization of the mechanism of DKA inhibition in cell-based assays 
Compound RDS1759 was found to be the only derivative able to selectively inhibit HIV-1 
replication in cell-based assays and its RNase H function in biochemical assays (Table 2), without 
showing inhibition of RDDP function (data not shown). Therefore, we chose the ester/acid DKA 
couple RDS1759/RDS1760 to investigate in more detail their mechanism of action in cell-based 
assays. FACS and qPCR analyses were performed to detect which step of viral replication is 
targeted by these inhibitors. MT4 cells were infected with the NLENG1-ES-IRES wt HIV-1 
containing a Green Fluorescent Protein (GFP) reporter system and treated with 10 µM 
concentration of RDS1759 and RDS1760 DKAs at the time of infection or 10 hours post infection 
(p.i.), since this time point is considered to occur at the end of the reverse transcription window 
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(Arts & Hazuda 2012). High mean and low mean fluorescence indicates expression from integrated 
viral DNA and unintegrated viral DNA respectively, as described previously (Gelderblom et al. 
2008). Samples were collected and analyzed by FACS at 48 and 72 hours p.i. quantifying i) the 
percentage of GFP positive cells (%eGFP), indicating the relative number of infected cells, that is 
overall reduced by reverse transcription inhibitors such as EFV; ii) the percentage of High Mean 
Fluorescence (%HMF), indicating the realtive number of infected cells with integrated viral DNA, 
which is selectively affected by integration process inhibitors such as RAL (Fig. 24A-C). Data on 
viral replication showed that ester derivative RDS1759 reduced %eGFP cells by 68% and 43% at 48  
 
 
Figure 24. Inhibition of HIV-1 replication by DKAs. MT4 cells were infected with NLENG1-ES-IRES 
wt HIV-1 containing a GFP reporter system.  Panel A-C.  Samples were analyzed 48 hours post 
infection quantifying the number of emitting GFP cells (eGFP) versus the GFP intensity of emission, 
categorized in low intensity (M1), indicating expression from unintegrated viral DNA, and high 
intensity (M2), indicating integrated viral DNA expressing GFP. Panel A. MT4 infected (no 
inhibitor). Panel B. MT4 cells treated with 100 nM EFV. Panel C. MT4 cells treated with 200 nM 
RAL. Panel D-G. Samples were analyzed 48 (gray) and 72 (black) hours p.i., quantifying the 
percentage of total (M1 and M2) emitting GFP cells (panel D-E) and the percentage of High Mean 
Fluorescent cells (HMF) (M2) (Panel F-G) normalized to the percentage of the untreated control. 
Drugs (10 µM RDS1759, 10 µM RDS1760, 100 nM EFV, 200 nM RAL) were added at the time of 
infection (Panels D and F) and 10 hours p.i. (Panels E and G).  
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and 72 hours p.i., respectively (Fig. 24D-G). These results showed an inhibition pattern analogous  
to that observed for EFV, used as positive control, and suggested that RDS1759 inhibits the 
retrotranscription process as well. Surprisingly, inhibition of retrotranscription by RDS1759 was 
found to be time dependent since it was significantly reduced at 72 hours p.i.. In order to confirm 
this mechanism of action, drugs were added 10 hours p.i., and results showed a strong impairment 
of the effect of RDS1759 on %eGFP (only 30% on inhibition). Differently from RDS1759, the acidic 
derivative RDS1760 showed a HIV-1 inhibition pattern similar to that observed for RAL, used as 
positive control for IN inhibition, suggesting that RDS1760 mainly affects the integration step of 
the viral replication process. Subsequently, the viral DNA genomes formed during infection in the 
presence of the two DKAs were investigated by qPCR, total viral DNA and 2-LTRc DNA in the early 
phases of viral replication. First, 10 μM of RDS1760 and RDS1759 were added at the time of 
infection and DNA samples were collected after 4, 6, 8, 10, 24 and 48 hours (Fig. 25A-B). Then, 
DKAs were added 10 hours p.i. and DNA samples were collected after 24 and 48 hours (Fig. 25C-D). 
Results showed that RDS1760 followed the RAL profile in 2-LTR accumulation after 24 and 48 
hours either if added at the time of  viral infection or 10 hours later. 2-LTR circles accumulation 
has been described when HIV-1 integration was impaired (Delelis et al. 2010). Moreover, RDS1760 
caused a 30% decrease in total amount of viral DNA, which is higher than observed for RAL which 
was used as positive control and inhibited all integration events. Therefore, we could not exclude a 
partial inhibition of reverse transcription by RDS1760, even though its main target appears to be 
IN. Conversely, derivative RDS1759 induced a strong reduction in the formation of total viral DNA 
and followed the EFV profile until the time point at 10 hours. However, such a reduction was 
partially reversed at 24 hours, confirming a time dependent mode of action. Consistent with 
absence of IN inhibition, RDS1759 showed no accumulation of 2-LTRc DNA compared to  
untreated control. These results clearly indicate that RDS1760 primarily acts on IN, while RDS1759 
selectively inhibits reverse transcription in a time-dependent manner. To further confirm this 
hypothesis, we determined the viral inhibition rate by RDS1759 at 24 and 48 hours, observing an 
important shift in the EC50 values from 0.17 µM to 1.16 µM, respectively (Fig. 26). No shift of the 
EC50 value was observed with EFV.  
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Figure 25. qPCR kinetics of total and 2-LTRc DNA forms during a single round of HIV replication in 
presence of inhibitors. MT4 cells were infected with HIV-1 in the absence (●) or in the presence of 
10 µM RDS1759 (○), 10 µM RDS1760 (▼), 500 nM RAL (Δ) or 100 nM EFV (■), that were added at 
infection (Panel A-B) or 10 hours p.i. (Panel C-D). Samples were analyzed for total viral DNA and 2-
LTRc at different time point p.i. 
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Figure 26. Time-dependent inhibition of HIV-1 replication by RDS1759. HIV-1 infected MT4 cells 
were treated at the time of onfection with increasing concentrations of RDS1759 (Panel A) and 
EFV (Panel B). Percentage of GFP emitting cells was measured at 24 hours p.i. (●) and 48 hours p.i. 
(○). MT4 cell viability was also evaluated at 24 hours p.i. (▼) and 48 hours (Δ).  
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The observed time dependent effect could be due either to cellular metabolism or to the fast 
dissociation of the ligand from the target. Therefore, to clearly distinguish between these two 
possibilities the amount of integrated viral DNA was determined at 24 and 48 hours p.i., adding  
RDS1759 12 hours before infection, at the time of infection, 12 hours p.i., and also adding each 
compound twice (at infection and 12 p.i.), using RAL as a control (Fig. 27). Addition of the 
compounds 12 hours before infection led to a consistent decrease of viral inhibition only for 
RDS1759, highlighting the possibility of cellular drug metabolism. As described previously, the 
efficiency of RDS1759 is maximal when the drug is added with the virus (time 0) or when the 
compound is added twice (time 0 and time 12 hours p.i.). When RDS1759 is added 12 hours p.i., 
inhibition of integration occurred but to a lesser extent compared to RAL. Taken together, these 
data demonstrate that RDS1759 displays a weaker stability compared to RAL. More importantly, 
RDS1759 efficiently targets the reverse transcription step, whereas the integration step is 
inhibited less efficiently.  
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Figure 27. Effect of the time of RDS1759 addition on HIV-1 replication. HIV-1 infected MT4 cells 
were treated with 10 µM RDS1759 or 200 nM RAL at different time points. Samples were collected 
at 24 (RDS1759 white box, RAL black box) and 48 hours (RDS1759 gray box, RAL pale gray box) and 
integrated viral DNA was measured. 
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4.7 Discussion 
It has been previously reported that DKAs may act on both HIV-1 RNase H and IN functions and 
that some derivatives could inhibit one or both activities in the low micromolar range (Shaw-Reid 
et al. 2003) (Tramontano et al. 2005). More recently, a wider study on DKAs inhibition of both 
RNase H and IN functions categorized the compounds according to their ester or acidic function, 
with IN function preferentially inhibited by acidic DKAs and RNase H function equally inhibited by 
both ester and acid derivatives (Costi et al. 2013). In addition, even though a number of RNase H 
specific inhibitors have been identified, not one was specifically shown to actually inhibit reverse 
transcription in cell culture. 
In the present study we defined the binding site of 12 DKAs on the HIV-1 RNase H domain and the 
investigated their mode of action in cell culture. We synthesized new couples of diketoester and 
DKA derivatives with various structural features that were shown to inhibit RNase H and/or IN in 
the low micromolar range. In particular, some esters proved to selectively inhibit RNase H activity 
with little or no effect to IN. A docking model for DKAs binding within the RNase H domain 
suggested interactions between this series of compounds and a number of highly conserved 
residues surrounding the RNase H active site: R448, N474, Q475, Y501, R557(Alcaro et al. 2010). 
Interestingly, a different binding orientation was proposed for ester and acid derivatives into the 
RNase H domain because of the steric hindrance of the alkylic ester chain. Different interactions 
are thought to occur with residue Q745, and the lateral chain of R448 is thought to interact with 
the aromatic substituents on the pyrrole ring of diketoesters such as derivative RDS1711. These 
selected residues were changed to alanine by site directed mutagenesis. As these residues have  
critical functional roles, the catalytic efficiency was measured for both their RNase H and RDDP 
enzymatic activities, demonstrating a decrease of kcat/KM ratio for these RNase H primer grip 
mutants. In contrast, these mutations had no significant effects on RDDP function. Biochemical 
assays on  these mutants RTs showed an inhibition pattern by DKAs consistent with the calculated 
model and corroborated the hypothesis of a different binding orientation for esters and acids. In 
particular, mutation Q475A was discriminating between the two groups since, with respect to wt 
RT, the ester DKAs decreased their inhibition potency while the acidic counterparts increased it. 
The difference in binding orientation between ester and acid derivatives was further confirmed by 
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the inactivity of ester RDS1711 on the R448A RT, while no change in IC50 value was observed for 
the acidic counterpart RDS1712; corroborating the hypothesis that an interaction occurs between 
R448 and the benzyl group of RDS1711 that is absent in the RDS1712/RT complex.  
Importantly, in the present work we report a DKA derivative, RDS1759, that selectively inhibits the 
RNase H activity in the low micromolar range in biochemical assays, without effect on either IN or 
RDDP. RDS1759 also inhibits HIV-1 replication in cell-based assays with no evident toxic effects. IN 
contrast the acid counterpart, derivative RDS1760, instead was shown to preferentially target IN.  
To confirm that RDS1759 selectively target RNase H function in cell based assays,we performed 
FACS analysis on MT-4 infected cells and qPCR evaluation of early viral DNA products. Results 
showed that RDS1759 selectively target the reverse transcription process in cell-based assays, with 
less impact on integration events. This was however time dependent, with a decay of the 
inhibition of viral replication with time. Time of addition assays were performed to investigate this 
property and discriminate between cellular inactivation and fast dissociation from the target. Pre-
incubation in cell culture before viral infection compromised the effect of RDS1759 against HIV-1, 
while chronic exposure to the ligand completely restored the inhibition, supporting the hypothesis 
of some intracellular ligand inactivation. The speculation that some esterase metabolism could 
occur, generating the acidic counterpart is not supported by comparison of late effects related to 
inhibition of integration such as 2-LTRc DNA accumulation, that still occur for RDS1760 at 48 hours 
p.i. The more lipophilic nature of the ester DKA with compared to its acid counterpart may 
suggest, instead, a better diffusion into cellular compartments different from cytoplasma, were 
compound can be accumulated and/or metabolized, with a result loss of activity.  
In conclusion we demonstrated a different binding orientation for ester and acid DKAs into RNase 
H domain, and proved that DKAs interact with highly conserved residues not involved in the 
catalytic motif (R448, N474, Q475, Y501, R557). Moreover we identified a selective RNase Hactive 
site inhibitor, RDS1759, which selectively inhibited reverse transcription in cell-based assays.   
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Chapter 5.  
Site directed mutagenesis studies on HIV-1 RT shed light on 
the mechanism of action of a new RT-associated RNase H 
and RDDP dual inhibitor 
 
 
5.1 Introduction 
As described in the introduction, the DNA polymerase domain of the HIV-1 RT is located at the N-
terminus of the p66 subunit and exhibits the classical “right hand” conformation, while the RNase 
H domain is located on the other side of the p66 subunit, at the C-terminus, 60 Å from the 
polymerase active site. These two domains, separated by the connection domain, proved to be 
strongly interconnected and a functional interdependence has been suggested (Shaw-Reid et al. 
2005), since mutations at the N-terminus of the HIV-1 RT P226A, F227A, G231A, Y232A, E233A, 
and H235A can affect RNase H activity (Palaniappan et al. 1997), whereas deletions at the C-
terminus can strongly decrease DNA polymerization (HIzI et al. 1988). Such structural and 
functional interdependence is confirmed by the fact that i) mutations in RNase H domain were 
reported to influence nucleotide RT inhibitors (NRTIs) resistance (Gopalakrishnan et al. 1992) 
(Palaniappan & Wisniewski 1997) (Brehm et al. 2007), ii) the non-nucleoside RTIs (NNRTIs), i.e 
nevirapine and EFV, binding to RT has been shown to increase RNase H activity (Herman & Sluis-
Cremer 2013) and iii) RNase H inhibition has been linked to an increase in the AZT excision rate 
(Brehm et al. 2007).  
A number of compounds have been reported to inhibit both RT functions in vitro (Distinto et al. 
2013). In particular, hydrazones have been reported to inhibit RNase H function binding to an 
allosteric pocket close by the NNRTIs binding site (Himmel et al. 2006). More recently, a second 
hydrazone binding site, located in the RNase H domain, has been proposed (Felts et al. 2011) and 
further investigated (Gong et al. 2011) (Christen et al. 2012).   
With the aim of finding new HIV-1 RNase H inhibitors, we recently performed a successful ligand 
based virtual screen identifing new derivatives based on the scaffold of hydrazonoindolin-2-one 
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(Fig.26) that are active on both RNase H and RDDP functions in the low micromolar range (Distinto 
et al. 2012). This scaffold, further derivatized (Meleddu et al. submitted), consistently inhibited 
both enzymatic activities, in presence of diffent substituents. In order to dissect their binding sites 
a new derivative (Z)-4-(2-(2-(2-oxoindolin-3-ylidene)hydrazinyl)thiazol-4-yl)benzonitrile (RMNC6) 
was synthetised (Fig. 26) that is able to inhibit both RNase H and RDDP RT activities with IC50 
values of 1.4 and 9.8 µM, respectively (Table 5). A combination of biochemical and molecular 
modeling studies were performed to generate information that can be used in further rational 
drug design. Blind docking analysis suggested that RMNC6 could bind to two different sites: the 
first, close to the polymerase active site, the second one close to the RNase H active site. 
Conserved residues located close to both RDDP and RNase H primer grip regions were established 
as potentially critical for RMNC6 binding. Analysis of the susceptibility of the different point 
mutants to inhibition by RMNC6 showed a general agreement with the docking model, supporting 
the hypothesis that isatine derivatives may bind to two different RT binding pockets.   
 
                            
 
Figure 28. Chemical structure of hydrazonoindolin-2-one derivate and RMNC6. The main 
structural features are highlighted in color: an aromatic portion (red square); an hydrazono spacer 
(yellow square); a surce of hydrogen bonds (blue arrow); a second aromatic ring (green square). 
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5.2 Comparison with known RNase H inhibitors. 
Firstly, since many RNase H inhibitors such as DKA derivatives (Tramontano et al. 2005) act by 
chelating the cation cofactors in the catalytic site, we verified the possible RMNC6 chelating 
properties. We recorded its UV spectra in the absence and presence of Mg2+ ions, showing no 
significant changes in RMNC6 maximum of absorbance in the presence of 6 mM MgCl2, excluding 
the involvement of chelation in the mechanism of action (not shown). Secondly, since it is known 
that some RNase H inhibitors such as VU destabilize the RT heterodimer by binding to an allosteric   
pocket in the RNase H domain at the interface between p66 and p51 subunits (Masaoka et al. 
2013) the alterations of the HIV-1 RT thermal stability was determined by performing differential 
scanning fluorimetry analysis (Cummings et al. 2006) in the presence of increasing concentrations 
of RMNC6 as well as known inhibitors such as the NNRTI EFV, the RNase H active site inhibitor BTP 
and the allosteric RNase H inhibitor 2-(3,4-dihydroxyphenyl)-5,6-dimethylthieno[2,3-d]pyrimidin-
4(3H)-one (VU) (Chung et al. 2012) as controls. In accordance with previous studies (Masaoka et al. 
2013), we observed a Tm increase of < 2.0 °C in the presence of Mg2+ and BTP and a Tm decrease 
of 0.5−5.5 °C in the presence of VU. In contrast, both EFV and RMNC6 did not significantly affect  
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Figure 29. Effect of RT inhibitors on the thermal stability of p66/p51 HIV-1 RT. Panel A. The 
melting temperature of HIV-1 RT was measured in presence of increasing concentrations of 
different inhibitors: (▼) EFV, (○) BTP, (Δ) VU and (●) RMNC6. Panel B. Maximum HIV-1 RT thermal 
shift (ΔTm) observed in the presence of 50 µM concentration of compounds. ΔTm values are the 
average of triplicate analysis, standard deviations are indicated as bars. 
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RT thermal stability, suggesting that RMNC6 may have an allosteric binding mode different from 
VU and possibly similar to EFV (Fig. 29). 
 
5.3 Comparison with EFV: Yonetani-Theorell analysis and NNRTI resistant mutants.  
To investigate the RMNC6 mode of action with respect to EFV, we performed a Yonetani-Theorell 
analysis on the interaction between RMNC6 and EFV with RDDP function. Such analysis allows to 
discriminate if two compounds are kinetically mutually exclusive or non-exclusive measuring 
reaction velocity at several fixed concentrations of the inhibitor while titrating the second 
inhibitor. The reciprocal of velocity (1/v) is then plotted as a function of concentration for the 
titrated inhibitor. If the two compounds are binding in a mutually exclusive fashion, this type of 
plot results in a series of parallel lines. If the two compounds binds indiopendently, the lines in the 
Yonetani-Theorell plot will converge at the x-axis (Copeland 2013). Results showed that the 
RMNC6 and EFV are not kinetically mutually exclusive (Fig. 30). Interestingly, however, the 
calculated interaction constant α had a value of 1.2, suggesting a negative interference between 
the two compounds: EFV binding negatively influenced RMNC6 binding and vice versa. Because  it 
is known that HIV-1 RT mutations K103N and Y181C and Y188L confer resistance to the NNRTIs 
EFV, the effect of RMNC6 on these mutant RTs was also tested (Table 6). Results showed no 
significant variation in IC50 values for RMNC6 inhibition of mutant RTs relative to wt RT on both RT-
associated functions, demonstrating no implication for these residues in the RMNC6 binding and, 
hence, suggesting that RMNC6 mode of action differs from NNRTI, such as EFV.  
 
Table 6. Effects of RMC6 on RNase H and RDDP activities of wt and NNRTI resistant HIV-1 RTs. 
 
RMNC6 BTP EFV 
 
RNase H RDDP RNase H RDDP 
RT IC50 (µM)
a foldc IC50 (µM)
b foldc IC50 (µM)
a foldc IC50 (nM)
b foldc 
         
Wt 1.3 ± 0.3 1 9.8 ± 1.4 1 0.19 ± 0.03 1 23 ± 4.1 1 
K103N 2.3 ± 0.1 1.8 13.6 ± 1.0 1.3 0.22 ± 0.08 1.2 176 ± 25 7.6 
Y181C 2.1 ± 0.6 1.6 5.4 ± 0.3 0.5 0.23 ± 0.05 1.2 49.7 ± 9.1 2.2 
a
Compound concentration (± standard deviation) required to inhibit HIV-1 RT-associated RNase H activity by 50%.  
b
Compound concentration (± standard deviation) required to inhibit HIV-1 RT-associated RDDP activity by 50%.  
c
Folds of difference with respect to wt RT. 
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Figure 30. Yonetani–Theorell plot of the combination of RMNC6 and EFV on the HIV-1 RT RDDP 
activity. HIV-1 RT was incubated in the presence of RMNC6 alone (●) or in presence different 
concentrations of EFV: 4 nM (Δ), 8 nM (■), 16 nM (). 
 
5.4 Blind docking analysis. 
To create further insight into the RMNC6 binding mode blind docking studies on the whole 
structure of wt HIV-1 RT and RMNC6 was performed employing the QM-polarized ligand docking 
protocol utilizing Glide version 4.5, qsite version 4.5, jaguar 7.0 and maestro 8.5 (Schrodinger Inc, 
Portland, USA).  Due to the flexibility of the target and the different shapes of known inhibitors 
(Fig. 31), it was decided to carry out ensemble docking experiments. The major conformational 
changes in the NNRTI binding pocket were taken into account to perform a clusterization of the 
available RT complexes. In particular, the orientation of Y181, Y188, Y183 and primer grip β12-β13 
hairpin were considered (Fig. 31) (Paris et al. 2009). A representative of each different cluster was 
picked (Fig. 31) and the three dimensional structure of HIV RT was retrieved from the Protein Data 
Bank. 
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The obtained [RMNC6•RT] complexes were subjected to a post-docking procedure based on 
energy minimization and successive binding free energies calculation. The binding free energies 
(ΔG(Bind)) were obtained applying molecular mechanics and continuum solvation models using 
the molecular mechanics generalized Born/surface area (MM-GBSA) method ((Kollman et al. 
2000). By comparing the ΔG-MMGBSA values (table 7), we found that blind docking calculations 
indicated the presence of two sites that are energetically favored for isatine derivatives binding 
(Fig. 32). The first binding site (pocket 1), the most energetically favored, is located close to the 
DNA polymerase catalytic site and is contiguous to the NNRTI binding pocket, having an “L shape”. 
n this large space, RMNC6 can dock in two different orientations. In the first orientation I 
(orientation A), the compound is accommodated in a pocket located between polymerase catalytic 
domain and NNRTI binding pocket. This pocket was recently described as allosteric pocket of HIV-1 
RNase H function (Himmel et al 2006, Himmel et al 2009). It is characterized by Y181 and Y188 
residues in closed conformation, different from the  open conformation that characterize most  
NNRTIs (Fig. 33A). The docking results suggest that RMNC6 possibly makes critical interactions  
 
Figure 31. Details of co-crystals selected selected for docking analysis A. Chemical and crystal 
structures pdb codes of co-crystallized NNRTIs selected for the ensemble docking procedure. Panel 
B. Stereoview of the primer grip region and residues 181, 183 and 188 are shown in color, relative 
to the different crystal structures examined . 
with amino acid residues V108, Y188, P227, W229 and L234.  According to the second orientation 
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 with amino acid residues V108, Y188, P227, W229 and L234.  According to the second orientation 
 (orientation B), RMNC6 binding could involve amino acid residues P95, L100, V106, Y188, P225, 
L234, W229, P236, and Y318 (Fig. 33C). In particular, the hairpin formed by the β12 and β13 sheets 
(Jacobo-Molina et al. 1993) was involved with different residues in both putative orientations.  
The second putative binding pocket (pocket 2) is located in the RNase H domain, between the 
RNase H active site and the substrate-handle region, close to the interface of the two subunits p66 
and p51. Docking modeling suggested that in this site RMNC6 could be partially sandwiched 
between different secondary structural units, the sheet β21 and the helix αH in the p51, and the 
helix αB in the p66 subunit (residues 500-508) (Fig. 34).  Since the large number of possibilities 
suggested by the docking modeling, we wanted to better investigate the binding mode via site 
directed mutagenesis. 
                    
 
Figure 32. Binding sites of RMNC6 identified with blind docking experiments on the whole wt 
HIV-1 RT structure. HIV-RT shown in cyan ribbon. Residues of the two binding pockets are shown 
in yellow sticks. 
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Figure 33.  Putative binding mode of RMC6 and critical residues identified for RMNC6 binding in 
pocket 1. Panel A. orientation A.  Panel C:orientation B. Panel B-D) 2D depiction of RMNC6 and its 
respective interactions with RT residues:  pale yellow sphere indicate hydrophobic interactions 
with lipophilic residues. while the violet sphere represents the aromatic π- π stacking interaction. 
         
Figure34. Putative binding mode of RMC6 and critical residues ideentified for RMNC6 binding in 
the pocket 2. Panel A. Putative binding mode of RMC6 and critical residues identified for RMNC6 
binding in the pocket 2. Panel B. 2D depiction of RMNC6 and its respective interactions with RT 
residues. pale yellow sphere indicate hydrophobic interactions with lipophilic residues.  The red 
arrow indicates an hydrogen bond acceptor interaction. 
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Table 7. Ensemble docking results: binding free energies of [RMNC•RT] complexes. In bold are 
indicated the most favored binding orientations for pocket 1  (red) and pocket 2 (blue). 
 
RTconformation 
(pdb codes) 
Pocket 
G_MMGBSA 
(Kcal*mol) 
Orientation 
1ep4 1 -41.23  
1ep4 2 -36.22  
3lp2 1 -44.85 A 
3lp2 2 -42.58  
1rti 1 -33.26  
1rti 2 -40.49  
1tv6 1 -51 B 
1tv6 2 -48.74  
1vrt 1 -35.9  
1vrt 2 -32.44  
2zd1 1 -41.96  
2zd1 2 -32.06  
3q09 1 -39.25  
3q09 2 -38.48  
 
 
5.5 Influence of the amino acid residues in pocket 1 on HIV-1 RT inhibition by 
RMNC6. 
Given the calculated docking model, we selectively mutated a large number of residues in both 
pockets. Considering the extent of pocket 1, its surface was deeply explored by single site 
mutagenesis. The hairpin constituted by the sheets β12 and β13 was identified as potentially 
involved in RMNC6 binding for both orientations and therefore alanine scanning mutagenesis was 
performed on amino acid residues 224-231. Residues V108 and V106 were identified to be 
important for inhibitor binding to RT in orientation A and B, respectively, and therefore they were  
also mutated into Alanine. We then tested the effects of RMNC6 on both RNase H and RDDP 
functions of these mutant RTs using BTP and EFV as controls (Table 8). Interestingly, when the 
mutant RTs RNase H function was assayed showed a 6-fold reduction in IC50 value against E224A 
RT compared to wt RT RMNC6, and a 4- and 10-fold reduction against V108A and V106A RTs, 
respectively. In contrast, no major difference in IC50 value was observed against the other mutant 
RTs (Table 8). When the mutant RTs RDDP function was assayed, a similar pattern was found even 
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though the extent of reduction in the IC50 values was lower (1.4, 3.3 and 2.5 for E224A, V106A and 
V108A, respectively). 
 
 Table 8. Effects of RMC6 on RNase H and RDDP activities of HIV-1 RTs mutated in amino acid 
residues in pocket 1. 
  RMNC6 BTP EFV 
 RNase H RDDP RNase H RDDP 
RT IC50 (µM)
a foldc IC50 (µM)
b foldc IC50 (µM)
a foldc IC50 (nM)
b foldc 
         
V106A 5.3 ± 0.6 4.1 25.1 ± 2.3 2.5 0.16 ± 0.03 0.8 35.4 ± 2.2 1.5 
V108A 13.1 ± 2.5 10.1 33.0 ± 5.2 3.3 0.18 ± 0.04 0.9 21.3 ± 3.6 0.9 
Y188A 3.3 ± 1.5 2.5 20.9 ± 4.0 2.1 0.19 ± 0.08 1.0 28.3 ± 7.4 1.2 
E224A 7.9 ± 1.1 6.1 13.8 ± 4.2 1.4 0.15 ± 0.03 0.8 24.9 ± 0.7 1.0 
P225A 1.7 ± 0.2 1.3 3.1 ± 0.3 0.3 0.13± 0.06 0.7 19.5 ± 2.9 0.9 
P226A 1.9 ± 0.1 1.5 18.9  ± 0.7 1.9 0.29 ± 0.08 1.5 18.9 ± 2.4 0.8 
F227A 0.7 ± 0.1 0.5 15.2 ± 0.9 1.5 0.22 ± 0.04 1.2 61.5 ± 1.4 2.7 
L228A 1.5 ± 0.1 1.2 13.1 ±  1.9 1.3 0.10 ± 0.06 0.5 21.8 ± 3.8 0.9 
W229A 1.9 ± 0.5 1.4 15.4 ± 2.8 1.6 0.15 ± 0.08 0.8 22.9 ± 5.2 1.0 
M230A 0.5 ± 0.1 0.4 15.0 ± 3.5 1.5 0.14 ± 0.04 0.7 29.1 ± 2.2 1.3 
G231A 1.7 ± 0.4 1.2 10.8 ± 2.4 1.1 0.25 ± 0.03 1.3 67.7 ±3.5 2.9 
a
Compound concentration (± standard deviation) required to inhibit HIV-1 RT-associated RNase H activity by 50%.  
b
Compound concentration (± standard deviation) required to inhibit HIV-1 RT-associated RDDP activity by 50%.  
c
Folds of difference with respect to wt RT. 
 
 
5.6 Influence of the amino acid residues in pocket 2 on HIV-1 RT inhibition by 
RMNC6 
Among the hypothesized RMNC6 interactions with the amino acid residues in pocket 2 we chose 
to mutate residues A502 to Phenylalanine and A508 to Valine with the aim to reduce the space 
available for RMNC6 accommodation. In addition, we also mutated residues Y501 and N474 into 
Alanine, since they were previously shown to be involved in interaction of DKAs with the RNase H 
domain (see chapter 4) and are known to play an important structural role in the functional 
geometry of the area, as part of the RNase H substrate primer grip motif, and are highly 
conserved, as indicated by the drastic reduction in viral infectivity of mutant viruses (Julias et al. 
2002). Hence, we again tested the RMNC6 effects on both RNase H and RDDP functions of mutant 
RTs, using BTP and EFV as negative controls (Table 9). According to the model, when the mutant 
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RTs RNase H function was assayed, RMNC6 showed a 6- and 5-fold reduction in IC50 value against 
A502F and A508V RTs compared to wt RT. In addition, RMNC6 showed a total loss of RT inhibition 
on the RNase H activity of N474A and Y501A RTs. Importantly, the active site inhibitor BTP showed 
a 2-fold reduction in RNase H inhibition only against N474A RT, confirming a difference in binding 
mode with respect to RMNC6. In contrast, when the RDDP function was assayed, RMNC6 did not 
show any significant change in potency of inhibition of mutant RTs compared  to wt RT as 
expected. 
 
Table 9. Effects of RMC6 on the RNase H and RDDP activities of HIV-1 RTs mutated in amino acid 
residues individuated in pocket 2. 
 RMNC6 BTP  EFV 
  RNase H RDDP RNase H  RDDP 
RT IC50 (µM)
a foldc IC50 (µM)
b foldc IC50 (µM)
a foldc  IC50 (nM)
b foldc 
          
N474A > 100 > 70 12.7 ± 1.7 1.3 0.92 ± 0.01 2.1  20.1 ± 5.1 0.9 
Y501A > 100 > 70 6.6 ± 0.1 0.7 0.07 ± 0.002 0.5  24.1 ± 3.5 1.1 
A502F 13.0 ± 0.7 10.0 17.1  ± 2.1 1.7 0.17 ± 0.03 1.1  22.3 ± 1.5 0.9 
A508V 6.5 ± 0.7 5.0 19.3 ± 2.8 1.9 0.16 ± 0.05 0.8  24.7 ± 2.4 1.1 
a
Compound concentration (± standard deviation) required to inhibit HIV-1 RT-associated RNase H activity by 50%.  
b
Compound concentration (± standard deviation) required to inhibit HIV-1 RT-associated RDDP activity by 50%.  
c
Folds of difference with respect to wt RT. 
 
 
5.7 Kinetic studies on mutants 
These data on the partial loss in RMNC6 potency of RNase H inhibition observed for E224A, V108A 
and V106A RTs supported two different hypotheses. According to the first one, the reduced 
potency could be due to an impairment of a long-range effect of RMNC6 bound in pocket 1. 
According to the second one, the single mutations can lead to a long-range modification of pocket 
2 that alters the compounds binding in pocket 2. 
To examine this second hypothesis, the possibility of a long-range modification of the RNase H 
domain, we asked if these mutations could influence the RNase H function and evaluated the 
RNase H catalytic efficiency of all DNA polymerase domain mutants that exhibited a reduced 
RNase H inhibition by RMNC6. It is worth to note in this context, that residue E224 is highly 
conserved as it is involved in the DNA polymerase primer grip motive (Palaniappan & Wisniewski 
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1997). In addition, among the residues mutated in the RNase H domain, N474 and Y501 are also 
highly conserved since they are part of the RNase H primer grip motive and have been reported to 
possess a consistent reduction in RNase H activity (Rausch et al. 2002), see chapter 4, therefore we 
asked if A502F and A508V mutants also had ajtered in their kinetic parameters. Results showed a 
consistent reduction in kcat value compared to wt RT for all the mutant RTs considered, and a slight 
reduction in KM value for A508V, V106A,V108A and E224A, resulting in a loss of efficiency (kcat/KM) 
for V108A and E224A (2- and 3-fold, respectively), (Table 10). Overall, these results support the 
hypothesis of long-range effects on the RNase H domain of mutations in the polymerase domain, 
consistently with previously reported data (Palaniappan & Wisniewski 1997), that can affect 
RMNC6 binding to pocket 2.  
 
Table 10. Comparison of DNA polymerase independent RNase H activity kinetics of wt and 
mutant HIV-1 RTs 
 
  RNase H   
RT kcat (min-1) KM (nM) kcat/KM % of wt 
wt 113 ± 1.4 127 ± 5.0 0.89 100 
V106A 52.6 ± 5.6 69 ± 11 0.76 85.4 
V108A 19.4 ± 3.3 48.8 ± 3.9 0.4 44.9 
E224A 21.2±4.3 78.6 ± 14 0.27 30.3 
A502F 20.8 ± 1.0 273 ± 18 0.76 85.4 
A508V 51.7 ± 4.9 74.9 ± 6.8 0.68 76.4 
 
 
5.8 Discussion 
Since both RDDP and RNase H activities of the HIV-1 RT are validated targets for drug development 
(Esposito et al. 2012; Distinto et al. 2013), but none of the approved drugs are able to inhibit both 
activities at the same time, the challenge of identifying a single molecule able to inhibit both 
functions at the same time is becoming more appealing in the attempt to minimize the occurrence 
of selection of drug resistant strains and reducing the administered drugs burden. In the past ten 
years, a number of compounds(Himmel et al. 2006; Esposito et al. 2011; Distinto et al. 2012) have 
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been reported to inhibit both RT-associated RNase H and RDDP functions. The third part of this 
work was focused on the characterization of the binding mode of a new scaffold identified in a 
virtual screening (Distinto et al. 2012). The RMNC6 derivative was able to inhibit both HIV-1 RT 
RNase H and RDDP functions in the low micromolar range and showed, via differential scanning 
fluorimetry, to behave differently from known RNase H active site inhibitors, that have been 
shown to stabilize RT against thermal denaturation (Su et al. 2010), and interface inhibitors, that 
have been shown to destabilize RT (Masaoka et al. 2013). Interestingly, RMNC6 behaved more 
similarly to the allosteric NNRTI EFV. Even though RMNC6 was not active against viral replication 
(data not shown), the dissection of its mode of action was particularly valuable. 
Blind docking analysis suggested as favorite two putative binding  pockets (Table 7 and Fig.32-34). 
In the pocket 1 RMNC6 exhibits two different binding orientations. In the orientation A in pocket 1 
(Fig. 33A) the compound occupies an allosteric site located between the polymerase catalytic 
region and the NNRTI pocket 50 Å from the RNase H catalytic site, previously reported to be the 
binding site of hydrazones derivatives (Himmel et al. 2006), in the orientation B RMNC6 occupies 
the NNRTI pocket, where most known polymerase inhibitors bind. Pocket 2 is a site located 
between the RNase H active site and the substrate-handle region (Christen et al. 2012). Such in 
silico analysis support two possible modes of RMNC6 action: i) RMNC6 could preferentially bind to 
one of the two pockets and have both short- and long-range effects; ii) RMNC6 could bind to both 
sites and act by short-range effects on the two functions. According to the first mode of action, 
RMNC6 would exert its RDDP and RNase H inhibition by  binding either into pocket 1 or into 
pocket 2. The binding into pocket 1 would have a short-range inhibition effect on RDDP activity 
and a long-range inhibition effect on the RNase H activity. So it would act opposite to NNRTIs such 
as nevirapine and EFV that were shown to destabilize the 3’-end of the DNA primer in the DNA 
polymerase active site and to promote RT-mediated polymerase-independent RNase H cleavages 
(Herman & Sluis-Cremer 2013). The binding into pocket 2, would have a short-range inhibition 
effect on RNase H activity and a long-range inhibition effect on the RDDP activity. Differently, 
according to the second mode of action, RMNC6 would bind to both individual RT pockets and its 
activity would be due to short-range inhibition effects, so that its binding to each site would be 
responsible for the inhibition of one function.  
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To investigate each of these possibilities we performed enzyme kinetics and site directed 
mutagenesis studies. The RMNC6 binding into pocket 1 (in orientation B), located in the 
polymerase domain, was the most energetically favored by modeling calculations (Table 7), 
however results of the assays with the mutant RTs led neither to incontrovertible evidence of 
RMNC6 binding, nor to a clear discrimination between the two proposed binding poses. The 
results, however, could not exclude the RMNC6 binding to pocket 1. In fact, given the magnitude 
of the pocket and the high RT flexibility, the very limited reduction in potency of inhibition of 
RDDP function by RMNC6 could be due to the fact RMNC6 could accommodate in pocket 1 
switching between the two binding orientations, to compensate the loss of affinity introduced 
with the changes in amino acid residues. Also kinetic analysis of the interaction between RMNC6 
and EFV showed no interference between the two compounds (Fig.30), even if they are not 
kinetically mutually exclusive, supporting the possibility that RMNC6 may bind in the large pocket 
1 even in the presence of EFV.  
Binding into pocket 2, located in the RNase H domain, had previously been reported for 
Hydrazones derivatives that exhibit inhibitory activity against RNase H function (Felts et al. 2011; 
Gong et al. 2011; Christen et al. 2012). When bound to this site RMNC6 might nudge the RNase H 
domain into a position in which the active site is no longer able to catalyze cleavage of RNA from 
the DNA:RNA duplex. RNase H inhibition of the mutant RTs in pocket 2 by RMNC6 strongly support 
the hypothesis that RMNC6 interacts with a pocket comprising amino acid residues N474, Y501 
and A502, and that this binding is responsible for short-range inhibition of the RNase H function. 
The observed fully retained RDDP inhibition of these mutant RTs by RMNC6 also supports the 
hypothesis that RMNC6 could bind to both pocket 1 and 2, and that its RT inhibition is due to two 
different short-range effects. Analyses of the kinetic parameters, support this hypothesis since the 
partial loss of RMNC6 potency of RNase H inhibition against E224A, V108A and V106A RTs could 
be most probably due to a long-range effects of the mutation itself, that could alter the substrate 
binding in the RNase H domain (Palaniappan et al. 1997) as well as the RMNC6 binding in to the 
second site. This is also confirmed by alteration of the RNase H function kinetic parameters 
observed for these mutant RTs. 
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In conclusion we characterized a two-sites mechanism of action for the isatine-derivatived RNase 
H/RDDP dual inhibitor RMNC6, as a possibility for further development of RNase H/ RDDP dual 
inhibitors.  
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Chapter 6. 
Conclusions   
 
Since both HIV-1 RT-associated RNase H and RDDP functions are valid targets for drug 
development, the present work was focused on the identification  and characterization of new 
promising RHIs. This goal was pursued by two different approaches: the characterization of the 
binding pocket of new RNase H active site chelating agents and the exploration of the mechanism 
of action of dual RNase H and RDDP inhibitors.  
Given the similarities between the HIV-1 and PFV RNase H domains, determined by structural 
alignment and superimposition of the two RNase H domains, PFV RT was used as a tool to 
investigate its interactions with RHIs, with the purpose of identfying the corresponding residues 
involved in the interactions between HIV-1 RT RNase H and RHIs. We tested the effect of five HIV-1 
RHIs, known to interact with different HIV-1 RT pockets, on the PFV RT: four selective RHIs 
(RDS1643,  DHQ,  BTP, VU6) and one HIV-1 RDDP and RNase H dual inhibitor (NSC657589). 
Moreover, for comparative purposes, we included the non-nucleoside RT inhibitor EFV in the 
study. All RHIs inhibited the PFV RNase H function at concentrations comparable to the ones 
reported for HIV-1 RNase H, suggesting similar binding to two proteins. Among the selective RHIs 
tested, RDS1643, DHQ and VU6 also inhibited the FV RT-associated RDDP activity, suggesting 
differences in the protein’s structure and flexibility between PFV PR-RT and HIV-1 RT. NSC657589 
confirmed its ability to inhibit both functions also in PFV RT. EFV was inactive on PFV PR-RT, 
indicating the lack of NNRTI binding pocket in that enzyme, as reported for other retroviruses with 
monomeric RTs. These results  confirmed that NSC657589, as  previously hypothesized,  it does 
not bind to NNRTIs pocket. Since the structure of the PFV RNase H has been previously solved by 
NMR spectroscopy, NMR analysis was used to characterize the RDS1643 interactions with the 
protein. NMR titration and docking experiments identified a number of non-catalytic residues into 
the PFV RNase H active site region (T641, I647, Y672 and W703) that may be involved in RDS1643 
binding of. Due to the high structural similarity of PFV and HIV-1 RNase H we were able to propose 
an inhibitor binding site in HIV-1 RNase H by using structural overlays. Sequence and structure 
alignments with HIV-1 RNase H suggested that the compound may interact with the corresponding 
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HIV-1 RT residues T473, L479, Y501 and V518, some of which are conserved as they are located in 
the RNase H primer grip area.  We therefore demonstrate that PFV RNase H can be used as a 
model enzyme to analyze the binding of HIV-1 RHIs, and also to model the interactions between 
RT and RHIs using NMR. Furthermore, it can also be used to exclude the binding of inhibitors into 
the NNRTIs site.  
The important insights that came from FV RT results makes the further investigation into the DKA 
binding mode into HIV-1 RNase H active site appealing. The prototype DKA RDS1643 was further 
developed into six ester/acid DKA couples used as chemical tool to explore their binding region on 
RT, and to demonstrate their mechanism of action in cell culture, with particular attention to 
discriminate between RNase H and IN, the other closely related viral-coded polynucleotidyl 
transferase. Among the compounds tested on both RNase H and IN functions, most of the ester 
derivatives showed selectivity for HIV-1 RNase H versus IN, while acids inhibited both functions 
and were generally more effective against IN. Molecular modeling and site-directed mutagenesis 
of the RNase H domain showed a different binding orientation for ester and acid DKAs, and proved 
that DKAs interact with highly conserved residues not involved in the catalytic motif (R448, N474, 
Q475, Y501, R557). In particular, an ester derivative, RDS1759, selectively inhibited RNase H 
activity and viral replication in the low micromolar range, making contacts with residues N474, 
Q475 and Y501 in the RNase H domain. Quantitative PCR studies and FACS analysis showed that 
RDS1759 selectively inhibits reverse transcription in cell-based assays. Overall, we provide the first 
demonstration that RNase H inhibition by DKAs can be related not only to their Mg2+ chelating 
properties, but also to specific interactions with highly conserved amino acid residues in the RNase 
H domain. Furthermore, RDS1759 is the first compound which, to the best of our knowledge, has 
been definitively proven to inhibit viral proliferation by inhibition of genomic RNA hydrolysis by 
RT, through interactions with conserved residues on RNase H domain of the enzyme, and hence 
offering important insights for rational optimization of RNase H active site  inhibitors.  
The second approach was focused on the identification and characterization of new RNase H/ 
RDDP dual inhibitors. Starting from a previous virtual screening campaign (Distinto et al. 2012) 
wich identified a new isatine-based scaffold for dual functions RT inhibitors a new compound, 
RMNC6, was synthesized and shown to inhibit both RT-associated RNase H and RDDP activities 
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with IC50 values of 1.4 and 9.8 µM concentration, respectively. RMNC6 showed a mode of RDDP 
inhibition different from the NNRTIs, retaining full potency of inhibition on NNRTI resistant mutant 
RTs: K103N, Y181C and Y188L. Hence, the possibilities of binding of this derivative into the whole 
HIV-1 RT through blind docking experiment and site-directed mutagenesis was explored. Two 
different RT pockets were identified: the first one close to the polymerase active site and 
contiguous to the NNRTI binding pocket, and the second one located in the RNase H domain. 
RMNC6 was assayed against enzymes selectively mutated on residues hypothesized to be critical 
for compound binding, which included conserved amino acid residues both in the polymerase and 
in the RNase H primer grip regions. The mutagenesis study supported the hypothesis of  
independent binding of RMNC6 in both pockets, since the mutation of amino acid residues in the 
pocket located in the RNase H domain (N474, Y501 and A502) strongly affected RNase H inhibition 
by RMNC6, while fully retaining its ability to inhibit the RDDP activity of these mutant RTs. 
Therefore, RT inhibition by RMNC6 seems to be due to its binding to two different RT pockets that 
lead to two different short-range effects. Moreover, we higlighted the role of mutations V106A, 
V108A and E224A that, affected the RNase H function in spite of their location far away from 
RNase H active site, confirming a strong interdependence between the two domains. 
Overall we i) validated PFV RT as a useful tool for RNase H active site inhibitor development, ii) 
successfully identified an RNase H selective active site inhibitor (RDS1759) iii) characterized for the 
first time its broad interaction with conserved residues in the RNase H active site area, iv) 
confirmed its selective mechanism of action in cell based assays, v) characterized a two-sites 
mechanism of action for the isatine-derivatived RNase H/RDDP dual inhibitor RMNC6, opening the 
way for further characterization of its binding pocket needed to allow further rational optimization 
of the scaffold. 
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